Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

1997

Effect of AF64A on Rat Brain Septo-Hippocampal and Striatal
Cholinergic Systems: A Neurochemical and Molecular Analysis
Qing Ivy Fan
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Pharmacology Commons

Recommended Citation
Fan, Qing Ivy, "Effect of AF64A on Rat Brain Septo-Hippocampal and Striatal Cholinergic Systems: A
Neurochemical and Molecular Analysis" (1997). Dissertations. 3412.
https://ecommons.luc.edu/luc_diss/3412

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1997 Qing Ivy Fan

LOYOLA UNIVERSITY CHICAGO

EFFECT OF AF64A ON RAT BRAIN SEPTO-HIPPOCAMPAL
AND STRIATAL CHOLINERGIC SYSTEMS:
A NEUROCHEMICAL AND MOLECULAR ANALYSIS.

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

DEPARTMENT OF PHARMACOLOGY AND
EXPERIMENTAL THERAPEUTICS

BY
QING IVY FAN

CHICAGO, ILLINOIS
JANUARY, 1997

Copyright by Qing I. Fan, 1997
All rights reserved

II

ACKNOWLEDGMENTS

I would like to thank Dr. Israel Hanin personally for the guidance and support
throughout the my educational career at Loyola. I would also like to thank John M.
Lopes, Ph.D., Nancy A., Muma, Ph.D., David J. Peace, M.D., and Louis D. Van de
Kar, Ph.D. for taking time out of their busy schedule to serve in the committee.
I am also fortunate to have the opportunity to work with the wonderful people
in our lab: Dr. Ahmed El Tamer, Dr. Xin Zhang, Dr. Igor Prokopenko, Dr. Daniela
Amoroso, Dr. Seong Yun Kim, Gisela Kindel, Leah Sandiago, Chris Willson, and
Carisa Thomas.
My appreciation is also extended to all members of the Department of
Pharmacology for providing the means to complete this study.
This work is dedicated to my parents, Y angshi Fan and Meiyuan Shen, for their
support.

iii

TABLE OF CONTENTS
ACKNOWLEDGMENTS ...............................................................................................

111

LIST OF TABLES ············································· ...................... ································ .........

IX

LIST OF FIGURES············································································································

x

LIST OF ABBREVIATIONS·························································································· xn
ABSTRACT ...................................................................................................................... xvii
Chapter
I.

II.

INTRODUCTION............................................................................................

1

REVIEW OF RELATED LITERATURE ....................................................... 3
A.

Cholinergic System ......... ....... .... .. .. ........ .. ............................. .................. .. .. ... 3
A 1. Cholinergic System Markers
A 1. 1. Acetylcholine (ACh)
A 1. 2. Choline acetyltransferase (ChAT)
A 1. 3. Acetylcholinesterase (AChE)
A 1. 4. High affinity choline transport (HAChT)
A 1. 5. Low affinity choline transport (LAChT)
A 1. 6. Vesicular acetylcholine transport (V AChT)
A 2. Distribution of Cholinergic Neurons and Their
Projections in Rat Brain
A 3. Septo-Hippocampal and Striatal Cholinergic Systems
A 4. Axonal Transport ofCholinergic Enzymes
A 5. Effect of Nerve Growth Factor (NGF) on the
Cholinergic System

B. Choline Acetyltransferase ........................................................................... 10
B. 1. ChAT Protein
B. 1. 1. Half-life of ChAT
B. 1. 2. Isoform and molecular weight of ChAT
protein
B. 1. 3. Antibodies against ChAT protein

iv

B. 2.
B. 3.
B. 4.

III.

ChATmRNA
ChAT Gene
Regulation ofChAT Expressions
B. 4. 1. Physiological conditions
B. 4. 2. Axotomy and axonal transport blockade
B. 4. 3. Nerve growth factor (NGF)
B. 4. 4. Other factors
B. 4. 4. 1. Second messenger systems
B. 4. 4. 2. Some endogenous factors
B. 4. 4. 3. Antimitotic agents

C.

Alzheimer's Disease and Cholinergic Hypofunction ··-----··· ---------------·· -·· ·· -20
C. 1. Neurochemical and Histological Studies
C. 2. Correlation of Cholinergic Function and Mental Status
in Alzheimer's Disease Patients
C. 3. Clinical Effects of Cholinergic Agents on Alzheimer's
Disease Patients

D.

Effect ofEthylcholine Mustard Aziridinium (AF64A) .............................. 23
D. 1. Structure and Selectivity of AF64A
D. 2. Neurochemical Studies on the Effect of AF64A
D. 2. 1. Effect of AF64A on ACh level and release
D. 2. 2. Effect of AF64A on HAChT system
D. 2. 3. Effect of AF64A on cholinergic enzymes
D. 3. Histological Studies on the Effect of AF64A
D. 3. 1. Axonal transport blockade
D. 3. 2. Neuronal degeneration
D. 4. Effect of AF64A on Animal Behavior
D. 5. Effect of AF64A on Cholinergic Receptors
D. 6. Effect of AF64A on Genes and Gene Expression
D. 7. Treatment and Prevention of the Effects of AF64A

MATERIALS AND METHODS ................................................................... . 36
A.

Animals.........................................................................................................

B.

Preparation of AF64A Solutions ............................................................... 35

C.

Stereotaxic Surgery and Intracerebroventricular Infusion .................... 37

D.

Tissue Preparation ..................................................................................... 37
v

36

E. Total Protein Measurement

39

F. ChAT Activity Assay ................................................................................... 39
G. Isolation of Total RNA .............................................................................. 39
H. Semi-Quantitative Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
......................................................................... 40
H. 1. Reverse Transcription (RT)
H. 2. PCR Amplification of cDNA
I.

Labeling of pGEM Markers ········································································· 42

J.

Restriction Enzyme Analysis ············ ····· ·· ··············· ····· ············· ·· ·············· 43

K.

Detection of PCR Product

43

L. Isolation of Total Protein .......................................................................... . 43
M. Western Blotting Assay .............................................................................. 45
M. 1. Electrophoretic Blotting
M. 2. Immunological Detection of Proteins on
Nitrocellulose Paper
N.

Chemicals and Enzymes .......................................... .............. ................... 46

0.

Statistics ······································································································· 47

IV.

RESULTS ··························································· ···································· ·········· 48
A.

General Observation ··················································································· 46

B. ChAT Activity Studies .............................................................................. 48
B. 1. Septo-Hippocampal Pathway
B. 2. Striatum
C. Optimization ofRT-PCR Working Conditions ...................................... 50
C. 1. Setup of the Primer for PCR & Restriction Enzyme
Analysis ofChAT cDNA PCR Product
C. 2. Optimization of PCR Buffer Conditions
C. 3. RT-PCR Blank Controls
vi

C. 4. Optimization of the Number of PCR Cycles and the
Concentration of Two Pairs of Primers
D. Time Course Study of ChAT mRNA Steady State Level....................... 59
D. 1. Formula for the Calculation of Steady State Levels of
ChATmRNA
D. 2. Septo-Hippocampal Pathway
D. 3. Striatum
E. Time Course Study of the Amount of ChAT Protein .............................. 68
E. 1. Normalizing the Conditions of Western Blot Analysis
E. 2. Septo-Hippocampal Pathway
E. 3. Striatum
F. In vitro Studies for ChAT Proteins ································----························ 95
F. 1. Effect of AF64A on Purified Bovine ChAT Protein
F. 2. Effect of AF64A on ChAT Protein in Tissue
Homogenates
F. 3. Stability of the 45 KD Protein
V.

DISCUSSION .................................................................................................. 103
A. Response of the Septo-Hippocampal Cholinergic Pathway
to icv AF64A Infusion .............................................................................. 107
A. 1. Elevation ofChAT mRNA and Protein in the Septum
at an Early Stage.
A. 2. Long-Lasting Reduction ofChAT mRNA in the
Septum.
A. 3. Alteration of ChAT Protein in the Septo-Hippocampal
Pathway.
A. 4. Overall Summary of the Response of the SeptoHippocampal Cholinergic Pathway to AF64A icv
Infusion.

B. Response of the Striatal Cholinergic Region to icv AF64A
Infusion ....................................................................................................... 119
C. Response ofChAT Protein to AF64A Incubation ................................. 123
VI.

SUMMARIES .................................................................................................. 127

vii

REFERENCES __________________________________________________________________________________________________ 128
VITA ----------------------------------------------------------------------------------------------------------------- 152

viii

LIST OF TABLES
Table
1

Page
Invitrogen PCR Optimizer Buffers................................................................. 60

ix

LIST OF ILLUSTRATIONS
Figure

Page

1.

Schematic representation of the major cholinergic systems in the
mammalian brain. .............. ... .. .. ... ... .................... ................................... ..... . 7

2.

Structural similarity of AF64A with choline. ........................................ 25

3.

Structural similarity of AF64A with nitrogen mustard. ···························· 32

4.

Effect of AF64A on ChAT activity in the hippocampus ....................... . 51

5.

Effect of AF64A on ChAT activity in the septum. ································· 52

6.

Effect of AF64A on ChAT activity in the striatum. ································· 53

7.

Setup of primers for ChAT cDNA amplification and restriction
enzyme analysis. ........................................................................................ 55

8.

Autoradiograph of the effect of different PCR Optimizer™
(Invitrogen) buffer on amplification ofChAT and H3.3 cDNA
signal............................................................................................................. 61

9.

Autoradiograph ofRT-PCR control experiment. ··································· 63

10.

RT-PCR analysis ofChAT and H3.3 signals with increasing
amplification cycles. ·· ·· ····· ·········· ··· ····· ··· ······································ ··············· 64

11.

Autoradiograph of the competition effect of these two
pairs of primers. ·························································································· 66

12.

Effect of AF64A on ChAT mRNA expression in the
septum ............................................................................................................. 69

x

13.

Effect of AF64A on ChAT mRNA expression in
the striatum. .......... ... ...... ... .... ... ............. .. ... ................................................

72

14.

Correlation of Western Blot analysis with the measurement of
purified bovine ChAT protein amounts...................................................... 78

15.

Linearization of tissue ChAT protein. ....................................................... 80

16.

Effect of AF64A on ChAT protein expression in the
septum .......................................................................................................... 83

17.

Effect of AF64A on ChAT protein expression in the hippocampus.
87

18.

Effect of AF64A on ChAT protein expression in
the striatum. .. ........ ··... ·· ················ ································································· 91

19.

Effect of AF64A on purified bovine ChAT protein .................................. 97

20.

Effect of AF64A on ChAT protein of tissue homogenates. .................... 99

21.

Stability of the 45 KD protein. .................................................................... 101

22.

Schematic representation of the septo-hippocampal cholinergic
pathway and possible sites of action of AF64A. ... ............... ................ .. .... 104

23.

Summary of the response of the septo-hippocampal cholinergic
pathway to the icv infusion of AF64A. ..................................................... 118

xi

LIST OF ABBREVIATIONS
a

alpha

y

gamma

µCi

.
.
m1crocune

µg

microgram

µl

micro liter

µM

micromolar

acetyl CoA

acetyl Coenzyme A

A Ch

acetylcholine

AChE

acetylcholinesterase

AD

Alzheimer's disease

AF64A

ethylcholine mustard aziridinium

araC

cytosine arabinoside

BChE

butyrylcholinesterase

bp

base pair

BSA

bovine serum albumin

cAMP

adenosine 3'5'-monophosphate

xii

CDF/LIF

cholinergic differentiation factor/leukemia inhibitory factor

ChAT

choline acetyltransferase

CNS

central nervous system

cRNA

complementary ribonucleic acid

dATP

deoxyadenosine triphosphate

DBB

diagonal band of Broca

dbcAMP

dibutyryl cAMP

dCTP

deoxycytosine triphosphate

DEPC

diethyl pyrocarbonate

dGTP

deoxyguanosine tri phosphate

DNA

deoxyribonucleic acid

dNTP

deoxynucleotide triphosphate

DTT

dithiothreitol

dTTP

deoxythymine triphosphate

FF

fimbria fomix

FUdR

5'-fluoro-2'-deoxyuridine

g

gram

g

gravity

H3.3

histone 3.3

HAChT

high affinity choline transport

xiii

HC-3

hemicholinium-3

HCl

hydrogen chloride

HLDB

horizontal limb of the diagonal band ofBroca

lC

intracerebral

lCV

intracerebroventricular

IL-6

interleukin 6

IR

immuno-reactive

Kb

kilo base

KCl

potassium chloride

kD

kilodalton

LAChT

low affinity choline transport

mA

milliampere

mAChR

muscarinic acetylcholine receptor

MgCh

magnesium chloride

ml

milliliter

mM

millimolar

MMSE

Mini-Mental State Examination

mRNA

messenger ribonucleic acid

MS

medial septum

nAChR

nicotinic receptor

xiv

NaCl

sodium chloride

NBM

nucleus basal is of Meynert

NFT

neurofibrillary tangles

ng

nanogram

NGF

nerve growth factor

NH2

nitrogen mustard

Oligo{dT)

oligodeoxythymidylic acid

PAGE

polyacrylamide gel electrophoresis

PBS

phosphate buffer saline

pmol

picomole

poly( At

polyadenylated mRNA

QA

quinolinic acid

RNA

ribonucleic acid

rpm

rotations per minute

RT-PCR

reverse transcription - polymerase chain reaction

SDS

sodium dodecyl sulfate

SP

senile plaques

Taq

Thermus aquaticus DNA polymerase

TBE

tris-boric acid-EDTA buffer

trkA

high affinity receptor of nerve growth factor

xv

u

units

VAChT

vesicular acetylcholine transport

w/v

weight/volume

xvi

ABSTRACT

Alzheimer's Disease (AD) is a progressive neurodegenerative disease that
affects a large proportion of old people. Extensive medical evidence has closely
connected AD with a dysfunction of cholinergic systems in the human brain.
Ethylcholine mustard aziridinium (AF64A) is a synthetic selective cholinergic
neurotoxin, which has been used to produce an animal model of AD. A single icv
injection of AF64A causes a long-lasting deficit of cholinergic function. One of the
hypotheses underlying the mechanism of AF64A's effects is that it induces this effect
by damaging DNA molecules of cholinergic neurons, which subsequently induces a
decrease in gene transcription and translation, in vivo. The purpose of this dissertation
was to test this hypothesis by determining the effect of AF64A on the level of mRNA
and protein of choline acetyltransferase (ChAT), a specific cholinergic marker, in the
septo-hippocampal and striatal cholinergic systems.
In the septo-hippocampal cholinergic pathway, during the first two days after
AF64A icv infusion, ChAT activity was reduced in the hippocampus but the levels of
the 67 kD ChAT protein did not change in the same brain region. Concomitantly,
AF64A caused a significant increase in ChAT mRNA levels in the septum, which was

xvu

followed by an increase in the amount of 67 kD ChAT protein amount and ChAT
activity in the septum. Seven days after the administration of AF64A, ChAT mRNA
levels in the septum were reduced below control level and stayed at this low level for
at least four weeks. Meanwhile, ChAT activity in the hippocampus continued to
remain low for at least four weeks, and this effect was matched by a decrease in the
amount of 67 kD ChAT protein.
In the striatal cholinergic system, icv infusion of AF64A did not cause
significant changes in ChAT activity, ChAT mRNA expression, or 67 kD ChAT
protein expression over the entire time course observed.
These data indicate that the long-lasting hypofunction of the septohippocampal cholinergic pathway caused by AF64A icv infusion may, in part, be
associated with its effect on gene expression of cholinergic neurons.

XVlll

INTRODUCTION

Clinically, a variety of neurological disorders are associated with the loss of
specific populations of neurons. Alzheimer's Disease (AD), Huntington's Disease, and
Parkinson's Disease (PD) present unique constellations of behavioral and neurological
abnormalities which result from the degeneration of cholinergic neurons in specific
regions of the brain. An animal model that is capable of mimicking the cholinergic
hypofunction of these diseases would help researchers to find a way to treat them,
especially, Alzheimer's Disease.
AD is a progressive neurodegenerative disease that is characterized by the
presence of senile plaques (SP) and neurofibrillary tangles (NFI) in the brain. Large
populations of people over the age of 65 years old suffer from mild to severe dementia,
which costs their relatives a considerable amount of money and requires extensive
personal attention to these individuals. Substantial medical evidence has closely connected
AD with a dysfunction of cholinergic systems in the human brain. This implies that an
efficient treatment of the symptoms of AD might be found by using a proper animal model
that replicates the cholinergic hypofunction of AD.
Ethylcholine mustard aziridinium ion (AF64A) is a synthetic neurotoxin, which
selectively

targets

cholinergic

neurons.

A

single

dose

intracerebroventricular

administration of AF64A causes a long lasting deficit of the cholinergic function of central

2

nervous system in experimental animals. The ability of AF64A to selectively damage
cholinergic neurons makes it an ideal agent with which to produce an animal model of
AD.
Choline acetyltransferase (ChAT) is the enzyme that catalyzes the biosynthesis of
the cholinergic neurotransmitter, acetylcholine (ACh). In AD patients, reduction of ChAT
activity is closely related to their symptoms of decreased learning and memory ability.
ChAT therefore is a specific cholinergic marker which has been used as an index of
cholinergic function.
This study focuses on the mechanism of the effect of AF64A, especially on the
possibility that AF64A affects DNA molecules in cholinergic neurons, in vivo. Since
AF64A belongs structurally to the family of mustard agents, and causes a long lasting
effect following single dose administration, the effects of AF64A might occur at the gene
level, or be due to a decrease in gene transcription, and/or translation.

CHAPTER II
REVIEW OF RELATED LITERATURE
A Cholinergic System:
The central cholinergic system constitutes a group of neurons that produce
acetylcholine (ACh) as a neurotransmitter in their nerve terminals. Several distinct groups
of cholinergic neurons in rat brain have been mapped out by the use of appropriate tracing
techniques and specific markers for cholinergic neurons.

A 1. Cholinergic System Markers:
A 1. 1. Acetylcholine (ACh):
Acetylcholine, the specific cholinergic system neurotransmitter, is synthesized in a
one-step reaction by choline acetyltransferase from its precursors choline and acetyl
coenzyme A (acetyl CoA), packed in vesicles within the nerve terminals, and released into
the synaptic cleft where it exerts its effect. Intracellular levels of ACh are maintained in a
dynamic steady state between its synthesis and release.

A 1. 2. Choline acetyltransferase (ChA1):
This enzyme is a specific marker for the functional status of cholinergic neurons,
and is responsible for the synthesis of ACh from choline and acetyl CoA. There are at least
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two active sites on this enzyme. One is the choline binding site; the other is the acetyl CoA
binding site.
A. 1. 3. Acetylcholinesterase (AChE):

AChE is responsible for terminating ACh function by degrading it to choline and
acetate in the synaptic cleft. This enzyme is not a strict cholinergic marker, since it also has
been found to be expressed in some non-cholinergic neurons (Bernard et al., 1995).
A. 1. 4. High affinity choline transport (HAChT):

Most of the reported results indicate that HAChT exists primarily in cholinergic
nerve terminal (Guyenet et al., 1973; Yamamura and Synder, 1973; Kuhar and Murrin,
1978; Jope, 1979). The HAChT system is responsible for taking up choline from the
extracellular space into nerve terminals to be used for ACh synthesis. This step is the ratedetermining step of the biosynthesis of ACh (Yamamura and Synder, 1973; Kuhar and
Murrin, 1978; Murrin, 1980; Salvaterra and Vaughn, 1989). The transport of choline
through this HAChT is a sodium dependent process. In brain tissue homogenates, HAChT
was localized to the synaptosomal fraction with a Km of 1-5 µM for choline (Guyenet et
al., 1973; Yamamura and Synder, 1973).
A. 1. 5. Low affinity choline transport (LAChT):

This choline transport system is not a strict cholinergic marker, has less specific
function, and is present in cholinergic and non-cholinergic cells which deliver choline for
cell membrane anabolism. In rat brain tissue, it is located in the cell body with a Km of 40-
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90 µM for choline. The transport of choline through LAChT is much less dependent on
sodium than is HAChT (Yamamura and Synder, 1973).
A. 1. 6. Vesicular acetylcholine transport (VAChT):

This transport system is located within the cholinergic nerve terminal, on the
membrane of the synaptic vesicles. Most of the synaptic ACh appears to be packaged
inside synaptic vesicles that do not contain ChAT and are impermeable to ACh. This
transport system is responsible for transporting synthesized ACh from the cytoplasm into
vesicles (Anderson et al., 1983). The ACh in the vesicles can then be released into the
synaptic cleft; although the free cytosolic ACh also can be released into the synaptic cleft
(Israel et al., 1984).
A. 2. Distribution ofCholinergic Neurons and Their Projections in Rat Brain:

In situ hybridization histochemistry studies, using labeled rat ChAT cRNA as
probes, have shown that a detectable cellular signal can be found in the striatum, basal
forebrain, pontomesencephalic tegmentum, various cranial nerve nuclei and spinal cord;
but not in the cerebral cortex (Oh et al., 1992; and Butcher et al., 1993) or hippocampus
(Oh et al., 1992; Butcher et al., 1993; Lauterborn et al., 1993). These studies suggest that
cholinergic neuronal cell bodies are located at the above mentioned areas except for the
cortex and hippocampus. However, a weak signal of ChAT mRNA was detected in the
hippocampus and cortex when reverse transcription polymerase chain reaction (RT-PCR)
methodology was used (Cavicchioli et al., 1991). This small amount of ChAT mRNA
observed in the hippocampus and cortex indicates that there might be a few intrinsic
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cholinergic neurons located in these two areas which contribute to this small amount of
ChAT (Tajima et al, 1991).
The localiz.ation of central cholinergic neurons has been illustrated very well in the
following schematic figure by Butcher and Woolf (1986) (Figure 1). One type of
cholinergic neuron, the intemeurons, are arrayed entirely within the neural structure in
which they are found. Cholinergic interneurons are located mainly in the striatum. Another
type of cholinergic neuron is the projection neuron. The cell bodies of most projection

cholinergic neurons are located in the basal forebrain and pontomesencephalic regions.
Neurons in the basal forebrain project to the entire nonstriatal telencephalon while the
pontomesencephalotegmental neurons project to the thalamus, other diencephalic loci, the
pontine, the medullary and cranial nerve nuclei.
The focus of this dissertation is on the septo-hippocampal cholinergic pathway
(projection neuron type) and the cholinergic neurons which are located in the striatal
region (intemeurons); both well-defined cholinergic systems.
A. 3. The Septo-Hippocampal and Striatal Cholinergic System:

The cholinergic neurons of the septum and diagonal band ofBroca (DBB) project
to the hippocampus through the fimbria-fomix (FF), form a part of the basal forebrain
cholinergic neuronal system (Mesulam et al., 1983). In this cholinergic system, ChAT
proteins are synthesized in the cell body and transported down to nerve terminal in the
hippocampal pathway is one of the most affected systems in brain of Alzheimer's disease
hippocampus, where ChAT is responsible for synthesis of ACh. The HAChT system

7

Figure 1. Schematic representation of the major cholinergic systems in the mammalian
brain (Butcher and Woolf, 1986). (ms, medial septa! nucleus; bas, nuclei
basalis; td, diagonal band nuclei; si, substantia innominata; poma,
magnocellular preoptic field; tpp, pendunculopontine tegmental nuclei; dltn,
laterodorsal tegmental nuclei; !CJ, Islands of Calleja complex).

8

primarily exists in the hippocampus where cholinergic nerve terminal located. The septohippocampal pathway is one of the most affected system in brain of Alzheimer's disease
patients, and has been used in regeneration studies and employing neurotrophic factors,
such as nerve growth factor (NGF) (Hefti and Knusel, 1990).
The striatum contains the highest level of ACh in the central nervous system.
Striatal cholinergic neurons are principally multipolar with aspiny or sparsely spined
dendrites (Woolf and Butcher, 1981 ). Cholinergic neurons located in the striatum are
interneurons, as has been demonstrated by fluorescent tracer experiments (Woolf and
Butcher, 1981 ). Both the cell body and nerve terminal of cholinergic neurons exist
within the striatum. Cholinergic neurons typically constitute a small proportion of the
total number of cells in the striatal regions in which they are found, and account for 1-2%
of the striatal neuronal population (Woolf and Butcher, 1981 ~ Phelps et al., 1985).

A. 4. Axonal Transport ofCholinergic Enzymes:
Most studies dealing with cholinergic enzyme transport have relied on detection of
enzyme activity for measuring transported enzymes. If the enzymes were synthesized and
transported as nonenzymatically active precursors they would not have been detected by
these studies (Salvaterra and Vaughn, 1989). Using histochemistry methodology,

Kasa et

al. (1973) located ChAT and AChE in cholinergic neuronal axons. It is believed that the
axonal transport of ChAT is unidirectional, as slow as 4 mm/day, and most of the
transported ChATis not associated with intra-axonal organelles (Tucek, 1975). In contrast
to ChAT, the axonal transport of AChE is bi-directional, and associated with vesicles and
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neurotubules, which indicates that AChE is bound to some components of the
membrane inside the axon (Brimijoin and Wiermaa, 1978). The orthograde transport
of AChE predominates during this bi-directional flow. The transport of AChE along
the axons is about 400 mm/day, which is much faster than that of ChAT (Tucek, 1975;
and Brimijoin and Wiermaa, 1978). These data suggest that AChE and ChAT are
transported by different mechanisms and at different velocities inside the cholinergic
neuronal axon.
A. 6. Effect of Nerve Growth Factor (NGF) on the Cholinergic System:

NGF is a polypeptide trophic factor which interacts with two distinctive types of
receptors, trk A and p75. NGF is synthesized and released from the target sites of
cholinergic neurons. After binding with its high affinity receptor (trk A) at the axon of the
cholinergic neuron, NGF is internalized and retrogradely transported to the cholinergic
neuronal cell body (Schwab et al., 1979; Korsching and Thoenen, 1983; Seiler, and
Schwab, 1984). NGF is necessary for the survival and maintenance of central cholinergic
neurons. It has been reported that NGF infusion can increase ChAT activity in normal
animals and restore cholinergic function in animals with cholinergic deficits (Hefti et al.,
1989).
Following chemical damage of cholinergic neurons via intracerebral injection of
the excitotoxin quinolinic acid (QA) into the striatum, there was a decrease in the number
of cells expressing trk A and ChAT; while the mRNA for trk A and ChAT in the
surviving cells was down-regulated. NGF treatment prevented the decrease in the number
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of the cells which express the above two markers in treated animals and increased their
expression in control animals. However, NGF failed to prevent the down regulation of
glutarnic acid decarboxylase (GAD) induced by QA (Venero et al., 1994) in the striatum,
which indicates that NGF is a specific cholinergic trophic factor.

B. Choline Acetyltransferase (ChAD
The specific cholinergic functional enzyme, ChAT, was first discovered by
Nachmansohn and Machado in extracts of rabbit brain (1943). This enzyme protein
apparently is synthesized in the cell body of the cholinergic neuron and conveyed to
synaptic sites of action in the slowly transported pool of proteins (Frizell et al.,

1970~

Kasa

et al., 1973~ Tucek, 1975).

B. 1. ChAT Protein:
B. 1. 1. Half-life ofChAT protein:
In cell culture, the half-life of human ChAT protein is longer than 24 hours (Hersh,

1992). In in vivo experiments conducted on rat brain cortex, double labeling with L-[114C]leucine and L-[4,5-3H] leucine has been used to estimate the half-life of ChAT protein
under steady-state conditions. The measured half-life of ChAT is 5.2 days (y.I enthold and
Mahler, 1975).
B. 1. 2. Isoform and molecular weight of ChAT protein:
ChAT protein has a very low expression in mammalian brain, which has been
estimated at about 0.0001% of the brain protein (Eckenstein and Thoenen, 1982). This
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makes it very difficult to obtain purified homogeneous ChAT protein, using the classical
affinity column method. Usually, a purification factor of more than 1,000,000 is necessary
to obtain the pure enzyme (Berrard et al., 1989). Based on the solubilizing characteriz.ation

of this enzyme, multiple forms of ChAT protein existing in mouse and rat brain have been
suggested (Benishin and Carroll, 1981; 1983); they have been identified as cytosolic
soluble and membrane-bound ChAT forms. The cytosolic soluble form ChAT protein
exists in supernatant when brain tissue is homogenized in phosphate buffer, while the
membrane-bound ChAT protein is only released into supernatant when detergent (Triton)
is present. An extra membrane-anchoring domain was expected to exist in membranebound ChAT protein. However, subsequently ChAT protein purified by immune-affinity
chromatography from rat and human tissue showed a single molecular weight peptide;
epitope maps produced from both soluble and membrane-bound ChAT were identical
(Bruce and Hersh, 1987). These results did not support the previous assumption that
isoforms of ChAT proteins exist. Most researchers now believe that ChAT is a singlesubunit globular protein (Salvaterra and Vaughn, 1989).
Several research groups have made efforts to purify and to characterize the ChAT
protein from rat brain tissue. Rat cortex ChAT protein appears to have a molecular weight
of 60-65 kD under non-denaturing conditions (Wenthold and Mahler, 1975). Most
investigators suggest that the purified ChAT protein from rat brain has a molecular weight
of about 67 kD (Dietz and Salvaterra, 1980; Schmidt and Rylett, 1993). Although multiple
protein bands around this molecular weight have also been reported, the tryptic peptide
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maps have indicated that they contain a nearly identical primary structure (Dietz and
Salvaterra, 1980). There is no evidence suggesting the existence of low molecular weight
ChAT protein in rat brain, although a low molecular weight ChAT protein has been
reported in bovine brain with a molecular weight of 34 kD (Malthe-S0renssen et al.,
1978). In rat, purified ChAT protein was isolated from whole brain tissue, thus, there is no
report on any possible differences ofChAT proteins among different brain regions.
B. 1. 3. Antibodies against ChAT protein:
Most antibodies raised against the ChAT protein bind to an epitope that is located
at, or near the enzyme active site (Houser et al., 1982; Levey et al., 1982; Eder-Colli et al.,

1989). Thus, these antibodies can be used to inhibit ChAT activity in a very specific
manner. There are, however, some antibodies which bind to an epitope in ChAT protein
which is different from the active sites (Eckenstein and Thoenen, 1982).
Antibody for ChAT protein raised from one species is capable of cross-reacting
with other species, indicating a certain degree of immunological conservation of the
protein structure of ChAT in mammals (Salvaterra and Vaughn, 1989).
B. 1. 4. Post-translation modification ofChAT protein:
ChAT protein can undergo post-translational modification by phosphorylation
(Bruce and Hersh, 1989; Schmidt and Rylett, 1993), but a change in ChAT activity after
this phosphorylation has not yet been established. Usually, the cytosolic fraction of the
ChAT is phosphorylated

under basal,

unstimulated

conditions.

However,

the
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phosphorylation of ChAT does not appear to regulate cholinergic neurotransmission by a
direct action on the catalytic activity of~e enzyme (Schmidt and Rylett, 1993).
B. 2. ChAT mRNA:
ChAT cDNA was first cloned from Drosophila melanogaster head (Itoh et al.,
1986). In mammals, a cDNA clone encoding the complete sequence of an active ChAT
was first isolated from porcine brain (Berrard et al., 1987), and subsequently from rat brain
(Brice et al., 1989; and Ishii et al., 1990), mouse spinal cord (Ishii et al., 1990) and human
spinal cord (Oda et al., 1992). Comparison of these cDNA sequences revealed a high
degree of amino acid sequence similarity among mammalian ChAT, but not with

Drosophila ChAT (Brice et al., 1989; Wu and Hersh, 1994). Based on the amino acid
sequence derived from the cDNA, there is no membrane-anchoring domain to be found in
ChAT protein (Habert et al., 1992). These data also contradict the assumption for the
existence of two isoforms of ChAT protein based on their solubilizing characterization.
Accordingly, the membrane-bound form and membrane-free form of ChAT might exist
due to differential post-translational processing, rather than due to difference in their
primary structure.
The size of ChAT mRNA in adult rats is about 4 Kb (Ibanez et al., 1991; Nawa et
al., 1991) and is expressed at a very low level in rat brain (Ibanez et al., 1991). Multiple
transcripts were observed in rat spinal cord (Kengaku et al., 1992). However, all of the
transcripts encoded the same ChAT protein; they were only different in their non-coding
5'-ends.
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B. 3. ChAT Gene:

In all species examined so far ChAT is encoded by a single gene (Wu and Hersh,
1994). In humans, the ChAT gene has been mapped to chromosome 10 (CohenHaguenauer et al., 1990). In rats, on the other hand, the location of the ChAT gene is still
not clear. The gene encoding ChAT protein in rat was first reported to include one 5'
noncoding exon and 14 exons accounting for the entire coding sequence, which
distributes over at least 64 Kb. The largest intron is 14 Kb that is located immediately after
the noncoding exon (Hahn et al., 1992). The gene encoding V AChT has recently been
localized within the first intron of the gene encoding ChAT and is in the same
transcriptional orientation (Bejanin et al., 1994; Erickson et al., 1994; Berrard et al., 1995),
which indicates these two specific cholinergic markers might be under control of the same
regulators.
However, three 5' noncoding exons in rat gene have been demonstrated lately
(Misawa et al., 1992; Kengaku et al., 1993), and there are three different promoter
regions. It is therefore conceivable that five different types of ChAT mRNA are formed by
a combination of differential alternative splicing of noncoding exons, and that multiple
promoters play a role in this step. In the ChAT gene promoter region, there is a TATA-like
element and numerous potential binding sites for transcription factors which include: AP1 (Hahn et al., 1992), Sp 1 (Hahn et al., 1992; Inoue et al., 1993), octamer-binding factor
(Kitamoto and Salvaterra, 1995), CTF/NF-1 (Hahn et al., 1992), and the nuclear
oncoprotein Myb (Hahn et al., 1992).
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The active sites of ChAT protein have also been located in the rat ChAT gene.
Exon 3 contains the amino acid sequence of EELDLPKLPVPPLQ, which was suggested
to be the choline interaction site (Finocchiaro et al., 1991); and exons 8 and 9 code for the
histidine residues that might participate in the catalytic reaction (Berrard et al., 1987; Brice
et al., 1989).

There are three promoters for ChAT gene which are responsible for transcription
of five different ChAT mRNA types. There is no knowledge on the identity of ChAT
mRNA expressed in the septum and striatum. If ChAT mRNAs are different in the septum
from striatum, this might indicate that different promoters are response for the regulation
of ChAT gene expression in these two brain regions. This would indicate that ChAT gene
expression in the septum and striatum might be under different regulation.
B. 4. Regulation ofChAT Expression:

B. 4. 1. Physiological conditions:
ChAT activity changes during different developmental stages (Large et al., 1986).
Levels of ChAT mRNA undergo the same developmental stage-dependent changes as
ChAT activity (Cavicchioli et al., 1991), although the changes in mRNA precede those
of the activity (Barber et al., 1989).

In aged rats, there is a decrease in ChAT activity in cortex, hippocampus and
striatum, but there is no difference in mRNA levels in the striatum and basal forebrain
(Alberch, et al., 1991; Ogawa et al., 1994). Age-related impairments in ACh-mediated
neuronal systems are caused primarily by disorders of post-transcriptional events.
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Further studies conducted in Drosophila, using a wild type and two mutant type
(temperature sensitive) flies, indicated that neurotransmission and the rate of
neurotransmitter biosynthetic enzyme gene transcription are coupled for the cholinergic
system (fajima and Salvaterra, 1992). At a permissive temperature (l 8°C), the mutant flies
attempted to compensate for production of more thermo labile form of enzyme (defective
enzyme), by producing and/or maintaining higher levels ofChAT mRNA when compared
to the wild type, although the mutant type flies have less ChAT activity. This indicates a
negative feedback response for the regulation of ChAT gene expression in this condition.
The wild type flies, on the other hand, increased their ChAT mRNA levels when they
were transferred from a permissive temperature to a restrictive temperature (32°C), to
adapt to the increase in synaptic activity which might be temperature dependent. These

data suggested a positive feedback mechanism by which higher ChAT mRNA levels
reflect a higher demand for ACh, to sustain cholinergic synaptic transmission at the higher
temperature. This study suggests that ChAT gene transcription is a very important step in
the regulation of cholinergic function~ and that this step is regulated by a balance of both
positive and negative feedback mediated through cholinergic transmission.
B. 4. 2. Axotomy and axonal transport blockade:
Injury in an axon can affect, in central cholinergic neurons, expression of ChAT,
galanin, and trk A mRNA. The direction of changes in ChAT mRNA expression has,
however, been reported to differ. In the peripheral system, axotomy caused a decrease in
ChAT mRNA expression in motoneurons (Piehl et al., 1995). However, in the central
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nervous system. one week after fimbria fomix transection (axotomy of septal-hippocampal
pathway), neurons in the horizontal limb of the diagonal band of Broca (HLDB)
showed an increase in ChAT mRNA without any change in ChAT protein levels,
followed by a steady decrease in ChAT mRNA and ChAT protein content for at least 8
weeks (Weiser et al., 1994). Different from what occurs following axotomy, tetrodotoxininduced blockade of neuronal activity did not change ChAT mRNA levels significantly,
although there was a significant increase in mRNA of galanin, which coexists with
acetylcholine in cholinergic neurons (Agoston et al., 1994).
B. 4. 3. Nerve growth factor (NGF):

It has been widely reported that NGF plays a prominent role in regulating the
function of forebrain cholinergic neurons (Hefti, 1986; Large et al., 1986; Dreyfus, 1989;
Williams and Oostveen, 1992). It is believed that NGF produces cholinergic neuronal
hypertrophy through induction of gene expression of the NGF receptor within the basal
forebrain (Higgins, 1989). Icv administration of NGF stimulates ChAT activity in the
forebrain of neonatal and adult rats (Gnahn et al., 1983; Hefti et al., 1984). NGF also upregulates ChAT mRNA expression both in neonatal and adult rats (Cavicchioli et al.,
1991; Lorenzi et al., 1992). This phenomenon of NGF up-regulating ChAT activity,
paralleled with an increase in ChAT mRNA in neonatal rats, indicates that during the
developmental stage, transcriptional regulation is very important.
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B. 4. 4. Other factors:
B. 4. 4. 1. Second messenger systems:
Various second messenger systems have been implicated as influencing the
properties of cholinergic cells in general, and ChAT activity in particular.
a). Chemicals which relate to cAMP have been used to induce ChAT expression
in cell culture. These include: cAMP (Hersh, 1992); cAMP derivatives, such as dibutyryl
cAMP (dbcAMP) (Brenneman and Warren, 1983 ); and phosphodiesterase inhibitors
(Brenneman and Warren, 1983). These agents can increase ChAT activity in immature
primary cell cultures as well as the cultured neuroblastoma cells. The increase in ChAT
activity can be blocked by cycloheximide and actinomycin D (Brenneman and Warren,
1983; and Kirshner et al., 1986), indicating that the increase of the ChAT activity involves
ChAT protein synthesis and might be regulated at the transcription level.
b). In addition to cyclic nucleotide modulation of ChAT, the effects of protein
kinase inhibitors K-252 and staurosporine on ChAT activity in rat spinal cord cultures
have also been reported (Glicksman et al., 1993). It is believed that protein kinase A
inhibits expression of the ChAT gene at the transcriptional level, by controlling the activity
of an enhancer element.
B. 4. 4. 2. Some endogenous factors:
a). Retinoic acid (RA), an endogenous derivative of vitamin A, plays a role in the
development of the nervous system. In sympathetic neuron cell cultures, RA increases the
specific activity of ChAT; concomitantly, RA reduces the specific activities of two
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catecholamine synthetic enzymes, tyrosine hydroxylase (Ill) and dopamine-hydroxylase
(DBH), and the level ofnorepinephrine (NE) (Berrard et al., 1993).
b). Cholinergic differentiation factor/leukemia inhibitory factor (CDF/LIF) and
interleukin 6 {IL-6): In cultured rat sympathetic neurons, 1 nM CDF/LIF induces mRNA
for ChAT, somatostatin (SOM), substance P, and vasoactive intestinal polypeptide (VIP);
lowering the mRNA ofTII, and ofneuropeptide Y (NPY) (Nawa et al., 1991). CDF/LIF
increases both ChAT mRNA and immunoreactivity (Oh et al., 1994). However, IL-6
induces 6-fold increases in ChAT mRNA without any change in ChAT immunoreactivity,
and without any effect on cell survival.
c). Hormones: Both thyroid hormones, T3 and T 4 have been reported to increase
ChAT activity in cultured neurons and in vivo, as well as to restore the decreased ChAT
activity caused by hypothyroidism (Hayashi and Patel, 1987; Hashimoto et al., 1994;
Juarez de Ku et al., 1994); the precise mechanism is unknown. Glucocorticoids have also
been reported to have different effects on the regulation of ChAT activity in several brain
regions (Torres et al., 1991), which might be through an activation of AP-1 by
glucocorticoids (Schmitt et al., 1995)
B. 4. 4. 3. Antimitotic agents:
Cytosine arabinoside (araC) and 5'-fluoro-2'-deoxyuridine (FUdR), cause an
increase in ChAT activity without changing the level of glutamic acid decarboxylase
activity in embryo septal cultures. However, when embryo striatal cultures were used,
incubation with araC or FUdR had no effect on ChAT activity. It is believed that the
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different microenvironment of these two brain regions contributed to these different
responses (Hayes et al., 1991 ).

C. Alzheimer's Disease and Cholinergic Hvoofunction:
Alzheimer's Disease (AD), is a progressive neurodegenerative disease, which may
affect up to 15% of the population over the age of 65 years (Whitehouse et al., 1982), and
500/o of the population over the age of 85 years (Fisher et al., 1993). AD is characterized
by the presence of senile plaques and neurofibrillary tangles in the brain cortex (Doumaud
et al., 1995) and hippocampus (Ball, 1977; Ransmayr, 1992).

In patients who suffer from

AD, multiple central neuronal system deficits have been observed. However, a chronic
deficiency in central cholinergic function has been consistently found in these AD patients.
The most severely affected pathways are the nucleus basalis of Meynert (NBM)-cortical
pathway (White et al., 1977; and Whitehouse et al., 1981 ), and the septal-hippocampal
(Peny et al., 1977; Ransmayr, 1992) pathway.
C. 1. Neurochemical and Histological Studies:
The cholinergic hypothesis of AD emerged from the findings of a reduced activity
of the enzyme ChAT in postmortem AD brain tissue (Bowen et al., 1976; Davies and
Maloney, 1976; Peny et al., 1977). Reduced activity of this enzyme has been consistently
shown in all subsequent studies (DeKosky et al., 1985), and extended to include losses of
a number of other cholinergic markers including AChE (DeKosky et al., 1985; Tune et al.,
1985), HAChT (Pascual et al., 1991), and the content of ACh (Davis et al., 1985).
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It has been hypothesized that the decrease in ChAT activity in AD patients might

be due to mutation of ChAT protein or the loss of a part of the particular isoform of this
enzyme. However, purified ChAT protein is identical in brains obtained from normal
people and AD patients. This rules out the idea of selective loss of one particular
isoform or the mutation of this functional enzyme to explain the reduced levels of
ChAT activity observed in AD (Bruce, 1985). The degeneration of cholinergic neurons
in the basal forebrain has been reported widely (Whitehouse et al., 1982; Hedreen et al.,
1984; Pearson and Powell, 1987). The expression of ChAT mRNA might be downregulated in the surviving cholinergic neurons in the NBM of patients with AD, raising the
possibility of functional restoration by stimulating ChAT synthesis (Strada et al., 1992)
C. 2. Correlation of Cholinergic Function and Mental Status in AD Patients:

In AD patients, it is believed that cholinergic hypofunction is closely related to
their symptoms of decrease/loss in learning and memory abilities. Comparing cholinergic
enzyme activity from biopsy samples and the level of cognitive function as measured by
the Mini-Mental State Examination (MMSE) from AD patients; a significant correlation
between the decrease in ChAT activity and mental status before death has been reported
(Perry et al., 1978; Wilcock et al., 1982; DeKosky et al., 1992; Bierer et al., 1995).
Moreover, ChAT activity in the cortex autopsied from AD patients was found to be
significantly lower when compared with control cortices (DeKosky et al., 1992),
indicating continuous decline of ChAT activity throughout the course of the disease.
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C. 3. Clinical Effects of Cholinergic Agents on AD Patients:
Since cholinergic hypofunction has been consistently found in AD patients and
correlated with their symptoms, replacement of lost cholinergic function has, therefore,
been thought of as having a potential therapeutic benefit for AD patients. This can be
accomplished by enhancing endogenous levels of ACh through the inhibition of its
degradation by AChE, or by directly mimicking its actions at postsynaptic muscarinic
receptors (mAChR); which could be performed by using AChE inhibitors or mAChR
agonists, respectively (Winblad et al., 1992).
Tacrine (tetrahydroaminoacridine), a mixed, reversible inhibitor of cholinesterase,
has been shown to significantly improve several measures of cognitive performance in
probable AD patients although not all patients responded to this agent (Minthon et al.,
1994; Pacheco et al., 1995; Woo and Lantz, 1995). A similar effect with other AChE
inhibitors, physostigmine (Cummings et al, 1993) and velnacrine maleate (Jackson et al.,
1995); and cholinergic agonists, such as arecoline (Soncrant et al., 1993), also have been
reported.
Based on animal research showing that NGF treatment benefits central cholinergic
neurons, an intracranial infusion of NGF to an AD patient has been tried. The result
showed that there is an improvement in memory, without severe side effects. This study
suggests that further clinical trials of NGF infusion in AD are warranted (Seiger et al.,
1993).
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D. Effect of Ethylcholine Mustard Aziridinium (AF64A):
Using the selective cholinergic neurotoxin AF64A, a rodent model of human brain
disorders has been developed, in which a central cholinergic hypofunction has been
induced (Mantione et al, 1981; Fisher et al., 1982; Fisher and Hanin, 1986; Hanin, 1990,

1994). This animal model exhibits behavioral, anatomical, and neurochemical deficits
analogous to those observed in AD. AF64A-induced cholinergic hypofunction is
expressed by both loss of some cholinergic neurons and impairment in the functioning of
the spared neurons (Pittel et al., 1992). The effects of AF64A on the cholinergic system
have been explored both in neurochemical studies and in animal behavioral tests.
D. 1. Structure and Selectivity of AF64A:
AF64A is a structural analogue of choline, except that two of the methyl groups of
choline have been converted to the aziridinium moiety in AF64A, and the third methyl
group has been elongated to an ethyl group (Figure 2).
Usually, only a single dose intraventricular injection is required to produce a longlasting cholinergic deficit in animals (Mantione et al., 1981). There have been some
arguments in the literature as to whether AF64A is really a selective cholinergic
neurotoxin, since some researchers have shown non-specific effects of AF64A (Levy et
al., 1984; Jarrard et al, 1984; Eva et al., 1987; Allen et al., 1988; Gomez et al., 1993).
However, this depends on how much AF64A is used and where it is administered (Baskey
et al., 1989; Kasa et al., 1986; Hanin, 1990). Since AF64A is structurally similar to
choline, it can be recognized by the choline transport system. When low doses of AF64A
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are used, AF64A is only recognized and taken up by the HAChT into cholinergic neurons
and would thus appear to be a cholinergic selective toxin, since HAChT only exists in
cholinergic neurons (Guyenet et al., 1973; Suszkiw and Pilar, 1976; Kuhar and Murrin,
1978; Jope, 1979). However, when a high dose of AF64A is used, it can be taken up by
the HAChT as well as the LAChT system into cells and thus cause an abundance of
damage without cell selectivity, since LAChT exists in all types of cells and is responsible
for uptake of choline for the synthesis of phosphatidylcholine which is one component of
the plasma membrane (Pittel et al., 1987; Uney and Marchbanks, 1987; Hanin, 1990).
D. 2. Neurochemical Studies on the Effect of AF64A:
D. 2. 1. Effect of AF64A on ACh level and release:

In vivo studies have shown that AF64A treatment can cause a decrease in ACh
content in rodent animal brain tissue (hippocampus, cortex, and striatum) which happens
as early as 1 day after its intracerebral (ic) or intracerebroventricular (icv) injection
(Mantione et al., 1983; Sandberg et al., 1984 b; Potter et al., 1986; Leventer et al., 1985,
1987; Blaker and Goodwin, 1987; Tateishi, 1987; Mouton et al., 1989; Murai et al.,
1994). In synaptosomes which were obtained from AF64A-treated rats, there was a
decrease in their ability to synthesize and release ACh (Leventer et al., 1985, 1987; Potter
et al., 1986; Mouton et al., 1988; Pittel et al., 1992). In vivo microdialysis experiments
have shown that AF64A can induce a dose-dependent decrease in extracellular ACh
release (Meana et al., 1992; Tajima et al., 1993).
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Choline

AF64A

Figure 2. Structural similarity of AF64A with choline.
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D. 2. 2. Effect of AF64A on the HAChT system:
Icv administration of AF64A caused a significant decrease in HAChT activity in
the hippocampus and cortex in mice and rats (Mantione et al., 1981, 1983~ Leventer et al.,
1987~

Chrobak et al., 1989~ Morley and Gamer, 1990~ El Tamer et al., 1992). Pretreatment

with excess choline, or with the specific HAChT inhibitor, hemicholinium-3 (HC-3), was
able to prevent the effect of AF64A on HAChT and to block other effects of AF64A,
which indicates that the toxic effects of AF64A are dependent upon its uptake via the
HAChT site (Davies et al.,

1986~

Chrobak et al., 1989, Brake and Pappas, 1994). Similar

results have also been obtained in cell culture studies (Santiago et al., 1995), in which 10
times higher concentrations of choline chloride than AF64A delayed or diminished the
neurotoxic effect of AF64A. These data indicated there is a competition between choline
and AF64A for the HAChT (Davies et al., 1986~ and Santiago et al., 1995).

In vitro, the effect of AF64A on choline transport was also studied in
hippocampal, striatal, and cerebrocortical synaptosomes. Synaptosomes prepared from
these three brain regions were equally sensitive to AF64A, and HAChT was more
sensitive to the toxin than the LAChT (Pittel et al., 1987). Choline and HC-3 protected the
choline transport against attack by AF64A (Curti and Marchbanks, 1984).
It also has been observed that AF64A and hemicholinium-3 were much less potent
in neuronal cultures than in synaptosomes (Kelley et al., 1988).
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D. 2. 3. Effect of AF64A on cholinergic enzymes:

In vivo:
Following icv administration of AF64A, ChAT and AChE in the hippocampus
were markedly decreased in a dose-dependent manner, but were unchanged in the
neocortex and striatum (Vickroy et al., 1985; Leventer et al., 1987; Chrobak et al., 1988;
El Tamer et al., 1992; Gaspar et al., 1992; Ricci et al., 1992). The activity ofChAT started
to decline in the hippocampus within 24 h (Hortnagl et al., 1991 ), and the reduction of
ChAT activity reached its maximum within 4-7 days and persisted for as long as several
months (Leventer et al., 1987; Hortnagl et al., 1991; El Tamer et al., 1992;). This
cholinergic marker (ChAn was most affected in the ventral part of the hippocampus
(Hortnagl et al., 199 I).
Although icv infusion of AF64A has no effect on the activity of cholinergic
enzymes the striatum, direct injection of AF64A in rat striatum caused a decrease in ChAT
activity (Sandberg et al., 1984 a, b, c). Meanwhile intracerebral (ic) injection of AF64A
into the NBM or cortex also caused a decrease in ChAT activity in the cortex.
Cell culture and in vitro:
Cell culture studies showed that ChAT activity decreased rapidly, long before cell
lysis occurs (Sandberg et al., 1985). Further in vitro studies showed that there was a
concentration- and time-dependent inhibition of the activity of partially purified ChAT by
AF64A. This effect could be prevented by co-incubation of the enzyme and AF64A with
choline but not with acetyl-coenzyme A. Similar phenomena have also been observed in
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tissue homogenate studies (Mantione et al., 1984). These data suggest that AF64A might
act as an irreversible active site directed inhibitor of ChAT (Sandberg et al. 1985), which
binds at the choline binding site of the ChAT protein.
D. 3. Histological Studies on the Effect of AF64A:
D. 3. 1. Axonal transport blockade:
AChE and ChAT are normally transported from the cell body, where they are
synthesized, by different transport systems down the cholinergic neuronal axon (Tucek,
1975). In 1985,

Kasa and

Hanin reported an interesting phenomenon. Following icv

injection of a high dose of AF64A (5 nmol/lateral ventricle), a heavy accumulation of
AChE along the axons of the septo-hippocampal pathway was observed. This observation
was interpreted as indicating that AF64A blocked axonal transport of this enzyme.
There is no direct evidence supporting the concept that the transport of ChAT
protein is also affected by AF64A treatment. However, some neurochemical studies
provide clues that there might be a blockade of ChAT transport as well. These clues are
based on results from AF64A/NGF experiments by Willson and Hanin (1995). In these
experiments, ChAT activity significantly increased in the septum following AF/NGF
treatment. This increase in ChAT activity was even higher than that observed in the
vehicle/NGF treated rats. In the hippocampus, on the other hand, ChAT activity in
AF/NGF treated rats was significantly lower than that in vehicle/NGF treated rats. These
data indicated the possibility of some kind of blockade of the transport of ChAT from
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septum to hippocampus following AF64A infusion, an accumulation of ChAT in the cell
bodies of the septum, and a progressive reduction of enzyme content in the nerve terminal.
D. 3. 2. Neuronal degeneration:
The loss of ChAT immunoreactive (IR) positive neurons following AF64A
administration has been reported by several groups of investigators. Following direct
injections in the hippocampus (Tonnaer et al., 1986; Messer et al., 1991 ), or icv infusion
of AF64A (Lorens et al., 1991; Chrobak et al., 1988), immunocytochemistry studies
showed ChAT-IR profiles revealing shrinkage and disappearance of cholinergic neurons
in the medial septum (ms) and DBB. These data implied a retrograde degeneration of
cholinergic neurons following injection of AF64A administration.

Meanwhile,

intracortical AF64A infusions caused a significant atrophy, but not degeneration, ofNBM
cholinergic cell bodies (Mouton and Arendash, 1990). This retrograde degeneration
starting at the nerve terminal also has been observed in primary neuron cell cultures under
low concentrations (<25µM) of AF64A treatment, which could be prevented by the
presence of high concentrations (SOOµM) of choline (Amir et al., 1988), indicating that
retrograde cellular atrophy might be associated with inhibition of presynaptic HAChT on
cholinergic neurons (Mouton and Arendash, 1990).
D. 4. Effect of AF64A on Animal Behavior:
AF64A treated rats exhibited a severe deficit in their working memory (Blaker and
Goodwin, 1987; Chrobak et al., 1987, 1988; Masuda et al., 1992; Murai et al., 1994)
when they were subjected to T maze or radial arm maze tasks. In open-field tests, the
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cholinergic lesion caused by AF64A infusion induced a dose-dependent increase in
activity (Sandberg et al., l 984c; Bailey et al 1986; Gaspar et al., 1992; Lamberty et al.,
1992). Animals also showed a significant reduction in their spatial learning ability when
the Morris water maze or hole-board exploration were conducted (Gaspar et al., 1992;
Lamberty et al., 1992; Nakamura et al., 1992; Opello et al., 1993).
The septo-hippocampal and the NBM-cortical cholinergic pathways are the most
affected systems in AD patients; both pathways are very important for the acquisition of
learning and memory in animals (Bartus et al., 1982). AF64A-induced cholinergic
hypofunction in these two pathways has been studied using behavioral tests. The
cholinergic deficits were confined to the hippocampus, which produced significant
learning and memory impairments in situations where intermediate or long term memory
formation is required (Walsh et al., 1985; Blaker and Goodwin, 1987; Chrobak, 1987;
Opello et al., 1993) Furthermore, following intracortical AF64A infusion, animals
exhibited deficits in their active avoidance ability (Mouton et al., 1989; Nakamura et al.,
1992).
D. 5. Effect of AF64A on Cholinergic Receptors:
It has been well defined that there are two types of cholinergic receptors (AChR),
nicotinic (nAChR) and muscarinic (mAChR) respectively. In mammalian brain, type one
mAChR (Ml receptor) are located at the postsynaptic plate, while most type two mAChR
(M2 receptor) are autoreceptors which are located presynatically. In rats, Ml receptors
were either unaffected, or showed super-sensitivity following AF64A administration
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(Vickroy et el., 1985; Moroi-Fetters et al., 1990; Ricci et al., 1992), whereas M2 sites were
reduced after injection of the neurotoxin {Ricci et al., 1992). Some investigators have also
reported that adaptive changes in nAChR and mAChR occur in AF64A treated rats which
are similar to those reported in AD patients (Potter and Nitta, 1993).
D. 6. Effect of AF64A on Genes and Gene Expression:
The suggestion that AF64A may be causing a long-term cholinergic hypofunction
due to damage of DNA molecules originated from the observation of its unique chemical
structure (Futscher et al., 1992). Besides choline, AF64A is also structurally similar to the
reactive intermediate of the antitumor agent mechlorethamine (nitrogen mustard, HN2)
(Figure 3), which is known as a chemotherapeutic agent that exerts its effect by acting
at DNA molecules (Lawley and Brookes, 1965). Both AF64A and HN2 contain a
highly reactive aziridinium moiety which can serve to crosslink DNA molecules and
subsequently cause the cytotoxicity.
To test this hypothesis, in vitro experiments were conducted, which showed
that AF64A was capable of producing extensive dose-dependent N-7 guanine alkylations
in DNA fragments in vitro, although no sequence specificity of this AF64A attack could

be discerned (Futscher et al., 1992). Moreover, in vitro studies also showed that AF64A
could inhibit cDNA transcription without selectivity, since all DNA molecules subjected
to AF64A in these in vitro studies, such as, N-myc, AChE, and butyrylcholinesterase
(BChE) were affected (Futscher et al., 1992; Lev-Lehman et al., 1994; Hanin et al.,
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AF64A

Nitrogen Mustard
(HN2)

Figure 3. Structural similarity of AF64A with nitrogen mustard.
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1995). Furthermore, G, C-rich genes appear to be more sensitive to AF64A than A, T-rich
genes (Futscher et al., 1992; Lev-Lehman et al., 1994).

In cell culture studies, AF64A induced-cytotoxicity was accompanied by DNA
lesions (Futscher et al., 1992) which supported the hypothesis that AF64A alters the
structure and function of cellular DNA, which might help to explain the observed longterm cholinergic deficits in vivo. Further studies conducted in cultured neuroblastoma cells
found that AF64A caused a transient decrease of steady state levels of both N-myc mRNA
and ChAT rnRNA, which also indicated that AF64A can affect gene expression in cell
culture systems and cause DNA damage without gene selectivity (Santiago, 1995).

In vivo, icv administration of AF64A (2 nmol/lateral ventricle)caused a transient
change in the steady state levels of AChE rnRNA in the septo-hippocampal pathway (LevLehman et al., 1994). The decrease in AChE mRNA in the septum was explained as an
effect of AF64A at the gene level of cholinergic neurons.
AF64A also caused changes in mRNA levels of secretogranin II (increases in the
hypothalamus, amygdaloid nuclei and the reticular thalamic nuclei), chromogranin B
(increase in the hippocampus, temporal cortex, substantia nigra compacta,) and a growth
factor VGF (increase in magnocellular neurons). The changes in rnRNA expression of
these peptides are however considered as a consequence of cholinergic deficits caused by
AF64A treatment, rather than due to a direct effect of AF64A (Mahata et al., 1993).

34

D. 7. Treatment and Prevention of the Effect of AF64A:
AF64A treated animals have been used to mimic the cholinergic hypofunction
aspect of AD patients and to screen for therapeutic agents which have the potential for
treatment in AD (Hanin, 1996). For example, AF102B and AF150(s), new muscarinic
agonists, highly selective for Ml receptors, were tested for their ability to reverse
cognitive impairments in a step-through passive avoidance task and in an 8-arm radial
maze (Fisher et al., 1989, 1991; Brandeis et al., 1995). These compounds may prove
useful for treatment of cholinergic deficiencies and cognitive impairments which have
been reported in Alzheimer's disease. However, AF102B also exhibited low toxicity
in this animal experiment, which should be a warning in future studies. Similar
studies have been also conducted using AChE inhibitors, such as physostigmine
(Yamazaki et al., 1991), and tetrahydroaminoacridine (THA) (Murai et al., 1994), and
cognition enhancers (Hanin, 1996).

In the interest of reversing or preventing the presynaptic cholinergic damage
caused by AF64A, some additional treatments have also been attempted, with some
success:
a) Transplantation of fetal cholinergic neurons into the hippocampus can attenuate
both the behavioral and neurobiological alterations induced by AF64A (lkegami et al.,
1989, 1990, 1991; Walsh and Opello, 1992; Emerich et al., 1992).
b) Application of some potential treatment chemicals with antioxidant properties,
such as tolcapone (Khromova et al., 1995), and Vitamin E (Johnson et al., 1988;
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Maneesub et al., 1993; Wortwein et al., 1994) has also been attempted. It has been
demonstrated that pretreatment with these antioxidants can attenuate the effect of AF64A
presynaptically, which would also include the attenuation of the decrease in ACh content
and ChAT activity.
c) NGF is the first neurotrophic factor which was identified as a cholinergic
trophic factor. NGF up-regulates cholinergic function in the intact animal. Persistent
treatment (14-28 days) with NGF following AF64A administration could conceivably
restore the ChAT activity in the hippocampus (Willson and Hanin, 1995).
This success of the chemical treatment by using NGF and Vitamin E, as well as
cholinergic tissue transplantation, on the AF64A induced animal model, may provide
clues for the treatment of AD.

CHAPTER III
MATERIALS AND METHODS
A. Animals
Adult, Sprague-Dawley rats (Zivic Miller Laboratories, Allison Park, PA)
weighing between 175-250 grams were used in this study. After shipping, rats were
housed in our animal room 10-14 days before they were subjected to the surgery. The
rats were housed 2-3 per cage, in a room on a 12 hour light-dark cycle. They had
access to food and water ad libitum.

B. Preparation of AF64A Solutions
AF64A was prepared as previously described by Fisher et al. in 1982. Briefly, an
aqueous solution of acetylethylcholine mustard HCl was adjusted to pH 11.5 with NaOH
and stirred at room temperature for 20 min, after which the pH was brought to 7.3 with
HCl and the solution stirred at room temperature for another 60 min. This solution was
prepared freshly prior to each experiment and kept on ice during the experiment. The
solution was used within 6 hours after its preparation.
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C. Stereotaxic Surgery and lntraventricular Infusion

Animals were anesthetized with equitensin* (3 ml/kg body weight) and positioned

in a Kopf small animal stereotaxic frame. Iodine (1%) was applied to the skin surface
prior to incision. Two needles (26 gauge) were passed through parallel drilled holes in the
skull and positioned bilaterally in the ventricles, at the following stereotaxic coordinates
from bregma: posterior 0.8 mm, lateral ± 1.5 mm and ventral 3.8 mm. AF64A (1.0
nmol/1.5 µI) or an equal volume of vehicle (distilled water prepared according to the same
procedure as the AF64A preparation), were infused bilaterally at a flow rate of 0.5 µI/min.
for 3 minutes. The needles were left in place for 3 minutes after completion of infusion,
then they were slowly pulled out. Postoperatively, chloromycetin ointment (1 %) was used
locally and wounds were closed with autoclips, and the rats received ampicillin (50
mg/kg) to protect them from subsequent infection.
* Eguitensin (100 ml): pentobarbital sodium (0.972 g), 4.25 g chloral hydrate,
2.125 g magnesium sulfate-7H20, 39.99 ml propylene glycol, 10.0 ml ethanol, and
distilled water added to bring the final volume up to 100 ml.

D. Tissue Preparation

In vivo study:
At predetermined time points (1, 2, 4, 7, and 28 days after AF64A infusion)
the rats were decapitated, and septum, hippocampus and striatum were dissected from
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each rat brain, frozen on dry ice immediately, and stored at -70°C until they were used
for assay.
Jn vitro study procedures:

a) Striatal tissues from four untreated rats were pooled together and
homogenized in 12 ml sodium phosphate buffer (75 mM sodium phosphate, pH 7.4).
The above preparations were aliquoted into equal amounts (50 µI/tube) and stored at
-70°C until used for further tests.
b) Purified bovine ChAT protein (Sigma C3388) was dissolved in sodium
phosphate buffer (1 unit per 50 µl), then aliquoted into equal amounts and stored at
-20°C until used for further tests.
c) Striatal tissue homogenates or purified ChAT proteins prepared as described
above were incubated with various concentrations of AF64A (0.5 µM - 0.5 mM for
purified ChAT protein, and 5 µM -5 mM for tissue homogenates) at 37°C for 30
minutes, then placed on ice. The ChAT activity assay was conducted immediately
after the AF64A incubation. The remaining samples (-30 µl for each sample) had 4 x
protein loading buffer* added (10 µl for each) and stored at -20°C for western blotting
assays.
4 x protein loading buffer (100 ml): Glycerol (400/o), 8% SDS, 0.260 M Tris, 1%
bromophenol blue, and pH= 6.8.
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E. Total Protein Measurement
Tissue proteins were measured spectrophotometrically, usmg the procedure
described by Lowry et al. (1951 ). Bovine serum albumin was used as standard.

F. ChAT Activity Assay
This assay was petformed as described by Fonnum (1975). Briefly, tissue
homogenates (10 µI) were added to 10 µI of buffer substrate mixture which contained:
sodium phosphate (pH 7.4), 75 mM; sodium chloride 600 mM; MgCh, 40 mM; eserine,
2.0 mM; bovine serum albumin (BSA), 0.05%; choline-iodide, IO mM; and [3H]-acetylCoA, 0.87 mM (18.6µCi/mmol). After 30 min incubation at 37°C, the tubes were placed
on ice and 150 µI of sodium tetraphenylboron (TPB) solution (75 mg TPB per ml 3heptanone) was added to each tube. After vortexing and centrifugation, 100 µl of the top
organic layer was taken to measure the amount of [3H] ACh extracted from the buffer,
using liquid scintillation spectrometry. Blank controls consisted of cold phosphate buffer
instead of tissue homogenates

G. Isolation of Total RNA
The isolation of total RNA was petformed according to the protocol which is
described by Chomczynski (1987). TRI REAGENT™ (mainly containing guanidine
thiocyanate and phenol) was used. Briefly, tissue samples were homogenized in TRI
REAGENT™ (50-100 mg/ml), and stored at room temperature for 5 minutes. Chloroform
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was added as 0.2 ml per ml TRI REAGENT™ originally used, vortexed for 15 seconds,
and stored at room temperature for 3 minutes. The samples were next centrifuged at
12,000 g for 15 minutes at 4°C. The upper, aqueous phase was transferred to a fresh tube,
and a second phenol/chloroform extraction was conducted. After the upper aqueous phase
was transferred again to a fresh tube, isopropanol 0.05 ml/ml TRI REAGENT™ was
added, and the samples then were stored at room temperature for 5 minutes. They were
next centrifuged at 12,000 g for IO minutes at 4°C to remove possible DNA
contamination. The liquid phase was then transferred into a fresh tube, isopropanol 0.45
ml/ml TRI REAGENT™ was added, and the samples then were mixed, and stored at
-20°C for 1-2 hours. Finally, the samples were again centrifuged at 12,000 g for IO
minutes, at 4°C. RNA was precipitated on the side and bottom of the tube. The RNA
pellets were washed with cold 75% ethanol and centrifuged at 12,000 g for 5 minutes at
4°C. After air-drying, the RNA pellets were next resuspended in DEPC-treated double
distilled H20, and stored in a -70°C freezer. The concentration of the final preparation of
total RNA was detected spectrophotometrically at 260 A..

H. Semi-Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR)

H. 1. Reverse Transcription (RT):
This procedure was performed according to the protocol for reverse
transcription from GIBCO BRL, with minor modifications. Briefly, a 20 µl reaction
volume was used for each sample. To make first strand cDNA from 2-3 µg total
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RNA, 1 µl Oligo (dT)12-1s (500 µg/ml) and sterile distilled water were added to bring
the volume to 12 µI. The mixture was heated up to 70°C for 10 min. and then rapidly
chilled on ice. The contents were collected by brief centrifugation. Then, to each
sample, 4 µl 5X First Strand Buffer (250 mM Tris-HCl, 375 mM KCl, 15 mM MgCb,
pH 8.3), 2 µl 0.1 M DTT, 1 µl Mixed dNTP (10 mM) and 1 µl (200 units) of
SuperScript RT were added. The contents were mixed gently, and the tubes were
placed at room temperature for 10 min., then incubated at 42°C for 50 min. The
reaction was stopped by heating the tubes at 95°C for 5 min. After chilling on ice the
contents were brought down to the bottom of the tube by brief centrifugation. This
RT-product was stored at -20°C until used.
H. 2. PCR Amplification of cDNA:
The oligonucleotides used for the PCR reaction were as follows:
Histone 3.3 5': CCACTGAACTTCTGATTCGC 3'
Histone 3.3 3': TTCTGTAGGTCGATCGTGCG 5'
ChAT

5': GGCTTACTACAGGCTTTACCAGAG 3'

ChAT

3': GTAGTGGAAGACGTAGAGGTCAAA 5'

The expected PCR products were 465 bp for ChAT and 214 bp for Histone
3.3.
The reaction was performed in a total volume of 50 µl for each sample. RTproduct (5 µl) was added to the mixture which contained 10 µl PCR Optimizer™
buffer A [Invitrogen: 300 mM Tris-HCI, pH 8.5, 75 mM (N~)S0 4 and 7.5 mM
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MgCh], 3 µI dNTP mix (2.5 mM each of dATP, dGTP, dCTP, and dTTP), 20 pmol
2

primer for each, 2 µCi (3000 Ci/mmol) a-3 p dCTP, I unit of Taq polymerase, and
PCR water* were used to bring the final volume to 50 µI. The polymerase
amplification was carried out for 32 cycles (95°C, 30 sec; 58°C, I min.; 72°C, 2 min.)
followed by a final extension cycle ( 72°C, 10 min.).
PCR water: It is highly purified double distilled water which was obtained
from lnvitrogene with PCR Buffer.

I. Labeling of pGEM Markers
The pGEM marker DNA (DNA molecular weight markers) purchased from
Promega was radiolabeled by using the following reaction. pGEM marker DNA (1 µI), 1
µI T4 Polynucleotide Kinase (10 units), 2 µI 10 X Kinase buffer (700 mM Tris-HCI, pH
32

7.6, 100 mM MgCh, 50 mM DTT), and 1 µI y- P ATP (10 µCi, 5000 Ci/mmol) were
combined in a microcentrifuge tube and brought to a final volume of 20 µI with distilled
water. The mixture was incubated at 37°C for 30 min, and the kinase reaction was
inactivated at 65°C for 10 min. The free incorporated nucleotide was eliminated by using
Ultrafree-MC Filters (MILLIPORE). The end-labeled DNA marker was stored at 4°C
until used.
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J. Restriction Enzyme Analysis
An aliquot of radiolabeled DNA (ChAT PCR product) obtained as described
above, was used for the following restriction enzyme digestion. DNA was added to 10
units of, respectively, Nco I in REact 3 Buffer* (50 mM Tris-HCI, pH 8.0, 10 mM
MgCh, 0.1 M NaCl); Pvu II in REact 6 Buffer* (50 mM Tris-HCI, pH 7.4, 6 mM
MgCh, 50 mM KCI, 50 mM NaCl); and Rsa I in REact 1 Buffer* (50 mM Tris-HCI,
pH 8.0, 10 mM MgCh), and incubated at 37°C for 60 min. After these restriction
enzyme reactions, samples were extracted with an equal volume of phenol:chloroform
and then the aqueous phase was recovered by centrifugation at 4,000 x g for 15 min.
*Reaction buffer from GIBCO BRL.

K. Detection of PCR Products
To the samples of PCR product, 6 x DNA loading buffer* was added the
samples were subjected to electrophoresis on 4% polyacrylamide gel {PAGE) in 1 x
TBE buffer at 100 volts until the BPB (bromophenol blue) dye had reached the
bottom of the gel. After fixing in 10% acetic acid, and drying with an air drier, the
gels were quantitated on a Betagen Betascope 603 analyzer. The ratio of the counts
between the investigated gene (ChAT) and the control gene (Histone 3.3) was
calculated for each sample. The gels were also exposed under Fuji film.
* 6 x DNA loading buffer: Bromophenol blue (0.25%), 0.25% xylene cyanol
FF, and 15% Ficoll (Type 400) in water. Stored at room temperature until used.
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L. Isolation Of Total Protein
Total proteins were obtained :from the same samples which were used to isolate
total RNA. The isolation of total protein was performed according to the protocol which is
described by MOLECULAR RESEARCH CENTER, INC., and TRI REAGENT™ was
used. Briefly, after the aqueous phase (containing RNA) was removed from the
homogenate, 0.3 ml of 100°/o ethanol per one mililiter of TRI REAGENT used for the
initial homogenation was added to the rest of solution. The samples were mixed by
inversion and stored at room temperature for 3 min .. The samples were next centrifuged at
2,000 g for 5 min. at 4°C, and the supernatants were used for further protein isolation.
lsopropanol as 1.5 ml per 1 ml of TRI REAGENT was added, and samples were mixed
and stored at room temperature for 10 min., then centrifuged at 12,000 g for 10 min. at
4°C. The supernatants were discarded, and the pellets were washed 3 times with a solution
containing 0.3 M guanidine hydrochloride in 95% ethanol. This washing solution as 2 ml
per 1 ml TRI REAGENT was added, and the pellets were stored in the washing solution
for 20 min at room temperature each time, then centrifuged at 7 ,500 g for 5 min. at 4°C.
Next, ethanol (100%) as 2 ml per 1 ml TRI REAGENT was added, samples were stored
at room temperature for another 20 min., and centrifuged at 7,500 g for 5 min. at 4°C.
After air drying, the protein pellets were resuspended in 1% SDS, incubated overnight at
50°C, then the samples were centrifuged at 12,000 g for 10 min. at 4°C. The supernatants
were collected and stored at -20°C for subsequent Western-blot analysis.
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M. Western Blotting Assay
M. 1. Electrophoretic Blotting:
Total proteins (30 µg) which were stored in protein loading buffer were heated up
to 95°C for 5 minutes, then subjected to electrophoresis in the 7.5% SDS-PAGE gel at a
consistent voltage of 100 volt in the Ix protein electrophoresis buffer (25 mM Tris, 192

mM glycine, 0.1 % SDS, and pH = 8.3). After the bromphenol blue dye has been run out
off the bottom of the gel, the gel was taken out. Next the gels were firmly and evenly
pressed against nitrocellulose paper (NCP) in an electrophoretic destaining chamber, with
the nitrocellulose paper facing the cathode. The proteins were then electrophoretically
transferred to NCP (BIO-RAD, 0.45 mm pore size in roll form) in the 1 X transfer buffer
(25 mM Tris, pH= 8.3, 192 mM glycine and 200/o methanol) at 100 volts for 2 hours or at
30 volt overnight, in a cold environment. The NCPs were saved for further analysis.
M. 2. Immunological Detection of Proteins on Nitrocellulose Paper:
The NCPs obtained as in M.1. were soaked in a blocking solution (100/o wt/vol.
nonfat dry milk, 1% calf serum, 0.02% sodium azide, 0.05% NP-40 in PBS) for 2 hours at
room temperature. After rinsing with PBS, the NCP were incubated overnight at 4°C, with
the primary antibody (Anti-ChAT, mouse host, Boehringer Mannheim, #1464272) in a
1:10 dilution in PBS, 5% BSA, 1% calf serum, 0.05% NP-40 and 0.02% sodium azide.
After rinsing with PBS, 15 min. x 1, and 5 min. x 2, the NCPs were incubated with the
secondary antibody (Anti-mouse IgGi, goat host, Boehringer Mannheim, # 100831) which
was linked with horseradish peroxidase, in a 1:500 dilution in PBS, 5% nonfat dry milk,

46
and 0.05% NP-40 for 2 hours at room temperature. Then, the NCPs were washed
thoroughly with PBS 20 min. x 1, and 5 min. x 4.
The signal was detected by using ECL (enhanced chemiluminescence)
Western blotting detection reagents (Amersham #RPN2209). The NCPs were
incubated in the detecting reagent for 1 min. at room temperature, and immediately
exposed to Hyper-film (Amersham) for various time periods.
The results were analyzed using an NIH Image 1.57 System. Gels were
quantitated with respect to uncalibrated optical densities (O.D) where gray scale
values were measured in the range of 1 to 256. 1 was equivalent to 100%
transmitance and 256 was equivalent to 0% transmitance. The O.D from an area
adjacent to the protein band was read as background. Standard curves showed good
linearization (correlation factor= 0.998).

N. Chemicals and Enzymes
Acetylethylcholine mustard HCl was obtained from UCB (Belgium). TRI
3

REAGENT™ was purchased from Molecular Research Center, INC. (MRC). [ H]-acetyl
coenzyme A was purchased from DuPont;

a-[32P]-dCTP

and

y-[32P]-dATP

were

purchased from Amersham. All other chemicals were purchased from Sigma unless stated
otherwise. Enzymes for RT-PCR and restriction enzyme analysis were purchased from
GIBCO BRL. Antibodies were purchased from Boehringer Mannheim. PCR buffer and
PCR water were purchased from Invitrogene.
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O. Statistics:
The data are represented as group means and standard errors of the means
(S.E.M.). The data were analyzed by two way analyses of variance (ANOV A). Group
means were compared by Newman-Keuls' test. Correlation analysis was conducted by
using GB-STAT.

CHAPTER IV
RESULTS
A. General Observations

AF64A treated rats were more aggressive compared to control animals.
When tissues were dissected, a softer septum was observed in AF64A treated
rats within one week after treatment. Twenty-eight days after the icv infusion of
AF64A, the septum from treated rats showed distinct shrinkage compared to control
animals at the same time point. At all time points, increased cerebral spinal fluid was
observed in dissected brain which confirmed findings which had been reported before.
No significant differences in hippocampal and striatal tissue between the control and
AF64A treated animals were observed over all the time points.
These markers have been used to serve as the first index of whether AF64A
treatment was successful.

B. ChAT Activity Studies
B. 1. Septo-Hippocampal Pathway:
The effect of single icv administration of AF64A (1 nmol/lateral ventricle) on
ChAT activity in the hippocampus was examined (Figure 4). Statistical analysis
48
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indicated that a significant AF64A treatment x time course interaction occurred
(F{4,32)

=

3.42, P

=

0.02). There was a significant decrease in ChAT activity

following the AF64A treatment (F{l,8)
observed (F(4,32)

= 4.94,

= 155.35, P < 0.001) and over the time course

P < 0.01) in the hippocampus. The decrease in ChAT

activity was observed as early as one day after AF64A infusion, ( 82.82 % of control; P
< 0.05) in this study. The most severe decrease in ChAT activity (61.39 % of control; P
< 0.01) in the hippocampus was observed at 7 days after AF64A infusion, and the

extent of the decrease lasted for at least as long as 28 days (62 % of control; P < 0.01),
the last time point observed in this study.
In the septum (Figure 5), on the other hand, the activity of ChAT increased
following AF64A administration. Statistical analysis indicated that a significant
AF64A treatment x time course interaction occurred (F{4,20)

11.3, P < 0.0001). A

=

significant alteration occurred in ChAT activity followingy AF64A treatment (F(l,5) =
96.84, P < 0.001) and over the time course observed (F(4,20)

=

12.06, P < 0.0001).

The increase in ChAT activity in the septum was transient. This increase was observed
starting at day 2 after treatment (143.73% of control; P < 0.01), and remained proximal
level until day 7 (164.36 % of control; P < 0.01). By 28 days after AF64A
administration, ChAT activity in the septum did not show significant difference from
control.
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B. 2. Striatum:
In the striatum (Figure 6), statistical analysis indicated that there was no
significant AF64A treatment x time course interaction (F(4,32)

=

0.81, P

=

0.53).

There was no significant alteration in ChAT activity following the AF64A treatment
and over the time course observed.
The alterations of ChAT activity in these different brain regions have been used
to serve as an index of whether AF64A treatment was successful.

C. Optimization ofRT-PCR Working Conditions

C. l. Selection of the Primer for PCR & Restriction Enzyme Analysis of ChAT
cDNA PCR Product.
Over the past few years, many researchers have attempted to quantitate ChAT
mRNA using various methods. Due to the low level of expression of ChAT mRNA in
rat brain tissue, Northern blot analysis and RNase protection analysis are not sensitive
enough for the detection of ChAT mRNA levels. Therefore, a more sensitive method,
semi-quantitative RT-PCR, was used for the purpose of measuring ChAT mRNA
levels in this study.
The primers for amplifying ChAT cDNA were designed based on the cDNA
sequence which was published by Brice et al. (1989). A set of forward (sense, 15001523) and reverse (antisense, 1941-1964) PCR primers were chosen by using a
computer program, Oligo 4.0. The ideal annealing temperature for this pair of primers
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Figure 4: Effect of AF64A on ChAT activity in the hippocampus. Animals were
decapitated at different time points after icv administration of AF64A (1
nmol/side, bilaterally). Enzyme assay was performed in duplicate on tissue
homogenates according to the procedure described in the Methods chapter.
The data were obtained from 4 - 9 animals per group. The activity of ChAT
in control group: mean± SEM (30.5 ± 0.76 nmol/mg protein/hr). Statistical
significance was calculated from a comparison of the AF64A and vehicleinjected rats, at the same time point (Neuman-Keuls test). * P < 0.05~ ** P
< 0.01.
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Figure 5: Effect of AF64A on ChAT activity in the septum. Animals were decapitated
at different time points after icv administration of AF64A (1 nmol/side,
bilaterally). Enzyme assay was performed in duplicate on tissue
homogenates according to the procedure described in the Methods chapter.
The data were obtained from 3 - 6 animals per group. The activity of ChAT
in control group: mean ± SEM (42 ± 1. 7 nmol/mg protein/hr). Statistical
significance was calculated from a comparison of the AF64A and vehicleinjected rats, at the same time point (Neuman-Keuls test). ** P < 0.01.
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Figure 6: Effect of AF64A on ChAT activity in the striatum. Animals were
decapitated at different time points after icv administration of AF64A (1
nmol/side, bilaterally). Enzyme assay was performed in duplicate on tissue
homogenates according to the procedure described in the Methods chapter.
The data were obtained from 8 animals per group. The activity of ChAT in
control group: mean ± SEM (120.3 ± 3.03 nmol/mg protein/hr). Statistical
significance was calculated from a comparison of the AF64A and vehicleinjected rats, at the same time point (Neuman-Keuls test).
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is 58°C, and the expected size of the PCR product is 465 bp. Restriction enzyme
analysis of this 465 bp PCR product was conducted with three enzymes, which were
chosen based on the ChAT cDNA sequence by using computer program DNASIS, and
produced unique cuts within the DNA to yield different sizes of DNA fragments: Nco

I, 366 & 99 bp; Pvu II, 293 & 172 bp; and Rsa I, 259 & 206 bp (Figure 7). These sizes
of the DNA fragments were expected according to the sequence of ChAT cDNA
(Brice et al., 1989).
C. 2. Optimization of PCR Buffer Conditions:

In this semi-quantitative RT-PCR study, a housekeeping gene, Histone 3.3, was
chosen as an internal control for both the reverse transcription and amplification. As
stated in my overview hypothesis, AF64A might cause non-specific gene damage, and
thus the histone gene of cholinergic neurons could also be damaged by AF64A.
However, in this in vivo system study, histone 3 .3 still can be used as a very good
internal standard to normalize the variation ofRT-PCR analysis from sample to sample
for the following reasons: It has been known that, in the central nervous system, the
ratio between neurons and astrocytes is one to ten. Meanwhile, cholinergic neurons are
not the only neuron type in any brain region. In the striatum, only 1-2 % of neurons
belong to the cholinergic system (Woolf and Butcher, 1981; Bolam et al., 1984; and
Phelps et al., 1985). Similar or even smaller populations of cholinergic neurons exist in
the septum. Therefore, less than 1 % of all the cells in the septum or striatum are
cholinergic neurons, and only those histone genes which exist in these less than 1 % of
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ChAT cDNA Sequence

PCR Product Sequence

Upstream primer
1501 GCTTACTACA

G

1

GGCTTTACCA GAGACTGGTG CCCACCTATG AGAGCGCATC 51

1551 CATCCGCCGC TTCCAGGAAG GTCGGGTGGA CAACATCAGA TCAGCCACTC 101
1601 CAGAGGCTCT GGCTTTTGTG CAAGCCATGA CTGACCACAA GGCTGCCATG 151
1651 CCGGCTTCTG AGAAACTG CA G'CTGCTGCAG ACAGCCATGC AGGCCCAGAC 201
Pvu II
1701 TGAGT ACACA GTCATGGCCA TAACCGGCAT GGCCATTGAC AACCATCTTC 251
Rsal
'
1751 TGGCACTGAG
GGAGCTGGCC CGAGACCTGT GCAAAGAGCC ACCTGAGATG 301
1801 TTCATGGATG AAACATACCT GATGAGCAAC CGGTTTGTCC TCTCCACCAG

351

1851 CCAGGTGCCC ACAAC,CATGG AGATGTTCTG CTGTTATGGA CCCGTGGTCC 401
Ncol
1901 CCAATGGCTA TGGAGCCTGC TACAACCCCC AGCCCGAGGC CATCACCTTC 451

...

1951 TGCATCTCCA GITT
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Figure 7: Setup of primers for ChAT cDNA amplification and restriction enzyme
analysis of the ChAT PCR product. Panel A. Sequence of ChAT cDNA
PCR product. A set of primers for amplification of ChAT cDNA was
designed based on the ChAT cDNA sequence published by Brice et al.
(1989). A 465 bp PCR product was expected. Three restriction enzymes
were chosen to verify the correctness of this 465 bp PCR product. Panel B.
Autoradiograph of the restriction enzyme analysis of the 465 bp ChAT
cDNA. The PCR product was incubated with the following enzymes which
produced unique cuts within the DNA to yield different size DNA
fragments: Nco I (366&99 bp ); Pvu II (293& 172 bp); and Rsa I (259&206
hp). Lane 1: DNA marker; Lane 2: PCR blank control; Lane 3: RT-PCR
blank control. Lane 4: Uncut 465 bp ChAT cDNA; Lane 5: Nco I; Lane 6:
Pvu II; Lane 7: Rsa I.

57

cells have a chance to be affected by AF64A. Most of the housekeeping gene histone
3.3, which exists in the remaining more than 99 % of cells will thus not be directly
affected by AF64A. So, a possible alteration of the expression of the histone gene
within the small population of cholinergic neurons would be neutralized by the large
pool of the expression of hi stone gene in the whole brain region.
According to the primer design, the expected size of PCR product from H3.3
was 214 bp (Santiago, 1995).
Utilizing an

optimized

buffer kit from

Invitrogen

(Invitrogen

PCR

Optimizer™), the efficiency of amplification of both H3.3 and ChAT cDNA were
tested in different buffer solutions which varied in pH and MgCh concentrations
(Table 1). There were clearly two products amplified in buffers A-F, H, and J. Only
H3.3 was amplified in buffer G, K, N, and P. There was no PCR product found in
buffers I, L, M and 0 (Figure 8).
C. 3. RT-PCR Blank Control.
To confirm the specificity of the RT-PCR products, a senes of control
experiments was conducted (Figure 9): 1) PCR blank control was used to exclude the
possibility of contamination happening during the amplification process. In this
control, RT-products were replaced by PCR water in the PCR reaction. 2) RT blank
control was used to exclude the possibility of contamination happening during the
reverse transcription process. In this control, during the reverse transcription reaction,
total RNA was replaced by PCR water, and this RT product was subsequently
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subjected to the PCR reaction. 3) Genomic DNA control was used to show, in the
event that there was genomic DNA contamination in the total RNA samples, what
would be observed as the final result of the RT-PCR. In this control, genomic DNA
I 00 ng was added in the PCR reaction tube instead of the RT-product. 4) Total RNA
control was used to exclude the possibility of genomic DNA contamination. In this
control, total RNA was subjected directly to the PCR reaction. Since Taq polymerase
does not recognize RNA as template and amplify it, any positive signal must come
from contaminating DNA. If the RT blank control and PCR blank control were
negative, then this signal may be due to contamination from the total RNA sample
itself.
Total RNA control was conducted here to confirm that the method of total
RNA isolation has efficiently eliminated all genomic DNA from the samples.
PCR blank control and RT blank control were used for each of the following
experiments.
C. 4. Optimization of the Number of PCR Cycles and the Concentration of
Two Pairs of Primers.
Buffer A, B, E, and F were further subjected to an optimization analysis for the
number of PCR cycles. Buffer A (pH = 8.5~ MgCh, 1.5 mM) consistently provided
good amplification of both H3.3 and ChAT cDNA PCR products (Figure IOA).
The range of linearity with regard to the number of amplification cycles was
determined to be 32 cycles since the H3.3 almost reached a plateau at 35 cycles, while
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ChAT started to show a very clear band at 30 cycles and was still within the linear
range for up to 45 cycles (Figure I OB).
Since the PCR product of ChAT cDNA is relatively small, an attempt to
increase this product was made by increasing the concentration of the primer for ChAT
cDNA. However, there was a severe competition between H3.3 and ChAT cDNA
primer (Figure 11 ). After adjustment, the final concentration of both pairs of primers
was fixed at 20 pmol of each primer for each sample.

D. Time Course Study ofChAT mRNA Steady State Level:
D. 1. Formula for the Calculation of Steady State Levels of ChAT mRNA.
The steady state levels of ChAT mRNA were quantified using RT PCR
amplification.
ChAT mRNA expression was calculated as follows:
1) First, from each individual sample, the counts of PCR products for both
ChAT cDNA and H3.3 cDNA were obtained from the reading of the Betagen Scope.
Then the ratios of the counts of ChAT over histone for each individual sample were
calculated from control and AF64A treated rats (Re and RA), respectively.

Re=

Cmmts of ChAT (control)
Cmmts of histone (control)

R = Cmmts ofChAT (AF64A-treated)
A
Cowits ofhistone {AF64A-treated)
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TABLE 1

Invitrogen PCR OptimizerTM Buffers

[MgCl2]
(mM)

1.5

2.0

2.5

3.0

8.5

A

8

c

D

9.0

E

F

G

H

9.5

I

J

K

L

10.0

M

N

0

p

pH
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Figure 8: Autoradiograph of the effect of different PCR OptimizerTM (Invitrogen)
buffers on amplification ofChAT and HJ.3 cDNA signal. Total RNA from
striatal tissue was reverse transcribed, and the polymerase amplification
was carried out for 35 cycles as described in the Methods chapter.
Predicted PCR products for ChAT and HJ .3 were 465 and 214 bp,
respectively.
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Figure 9: Autoradiograph of RT--PCR control experiment. Lane 1: DNA molecular
weight marker; Lane 2: PCR blank control; Lane 3: RT blank control; Lane
4: Genomic DNA control; Lane 5: Total RNA control; and Lane 6: RT-PCR
product. The upper band is the ChAT cDNA PCR product; the lower band is
the histone cDNA PCR product.
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Figure 10:

Reverse transcription-polymerase chain reaction (RT-PCR) analysis of
ChAT and H3.3 signals with increasing amplification cycles. Total RNA
(3 µg) from striatal tissue was subjected to RT-PCR analysis using ChAT
and H3.3 primers. Aliquots of the reaction were removed at 20, 25, 30, 35,
40, and 45 cycles. The expected PCR products were 465 hp for ChAT and
214 hp for H3.3 . Panel A: Autoradiograph of the RT-PCR reactions.
Panel B: Densitometric results after the gel was scanned in a Betagen
analyzer.
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Primer: [ChAT] = 6 µM
[His3.3] = 4 µM

1605
1198
517
396
350

ChAT=465bp

222

His 3.3=214bp

179
75

Figure 11: Autoradiograph of the competition effect of these two pairs of primer. The
PCR products of ChAT cDNA were increased along with the cycles, while
the PCR products ofhistone 3.3 cDNA were decreased.
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2). The average of Re (Re ) for each time point was calculated as:

Re= L:

Rel N

(where N =the number of rats for control group at each time point)

3). The percentage of the R (R %) from each individual sample (both control
and AF64A treated animals) compared to this Re value was calculated as:

Re % (or RA % )= [ Re (or RA ) I Re] x 100
4). The mean ± SEM of this

Re % or RA % was used to represent the

expression of ChAT mRNA in the final results.
D. 2. Septo-Hippocampal Pathway:
Total RNA isolated from rat septal tissue was first reverse transcribed to
cDNA. Then, the cDNA was amplified using two pairs of primer for ChAT and H3.3
respectively, and the steady state level of ChAT mRNA was calculated as described
above. Statistical analysis indicated that a significant AF64A treatment x time course
interaction occurred (F(4,20)

=

6.7, P = 0.001) in the septum. There was a significant

alteration in ChAT mRNA over the time course observed (F(4,20)

=

4.4, P = 0.01),

although there was no significance following AF64A treatment (F(l,5)

= 0.3199, P =

0.6). However, comparing AF64A and vehicle-injected rats at each time point using
Newman-Keuls test, AF64A treatment appeared to significantly affect ChAT mRNA
levels in the septum (Figure 12). A significant increase (up to 167% of control; P <
0.05) in ChAT mRNA levels was observed as early as 1-2 days after the administration
of AF64A; this increase was followed by a significant decrease (down to 42.5 % of
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control; P < 0.05) at 7 days after AF64A treatment. This reduction of ChAT mRNA
levels in the septum was still observed at day 28 (37.6 % of control; P < 0.05).
D. 3. Striatum.
In the striatum (Figure 13), statistical analysis indicated that there was no
significant AF64A treatment x time course interaction (F(4,28) = 0.63, P = .0.65).
There was no significant alteration in ChAT mRNA levels following AF64A treatment
(F(l,7) = 1.27, P = 0.3) and over the time course observed (F(4,28) = 0.38, P =0.82).

E. Time Course Study of the Amount of ChAT Protein:
E. 1. Normalization of the Conditions of Western Blot Analysis:
In this study, a monoclonal antibody which binds ChAT protein to an antigenic
determinant different from the active site was used to perform Western blot analysis
(Eckenstein and Thoenen, 1982). Even if ChAT protein had been alkylated by AF64A at
its active site and inactivated (Sandberg et al, 1985), it would still be recognized by
this antibody.
To test the ability of this antibody to recognize ChAT protein in its denatured
condition, commercially available (Sigma) purified bovine ChAT protein, was first
used to conduct a Western blot analysis. This antibody recognized two protein bands
from purified bovine ChAT protein at molecular weights of 68 kD and 66 kD,
respectively (Figure 14 A). This result confirmed what has been reported. The density
of the protein bands showed very good dose-dependent changes (Figure 14 B), with a
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Figure 12: Effect of AF64A on ChAT mRNA expression in the septum. Animals
were decapitated at different time points after icv administration of
AF64A {l nmol/side, bilaterally). RT-PCR was performed in duplicate on
septal tissue total RNA according to the procedure described in the
Methods chapter. The data were obtained from 6 animals per group.
Statistical significance was calculated from a comparison of the AF64A
and vehicle-injected rats, at the same time point (Newman-Keuls' test.). *
P < 0.05. Panel A: Autoradiographs of the RT-PCR reactions. Each
autoradiograph represents the result from one time point. Starting from the
left, the first three lanes are: DNA molecular weight marker (I); PCR
blank control (2); and RT-PCR blank control (3); respectively. For the
remaining lanes, each lane represents a result from an individual animal.
There are six animals in each group. Panel B: Densitometric results after
the PAGE gels were scanned in a Betagen analyzer.
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Figure 13: Effect of AF64A on ChAT mRNA expression in the striatum. Animals
were decapitated at different time points after icv administration of
AF64A (I nmol/side, bilaterally). RT-PCR was performed in duplicate on
striatal tissue total RNA according to the procedure described in the
Methods chapter. The data were obtained from 8 animals per group.
Statistical significance was calculated from a comparison of the AF64A
and vehicle-injected rats, at the same time point (Newman-Keuls' test).
Panel A: Autoradiographs of the RT-PCR reactions. Each autoradiograph
represents the result from one time point. Starting from the left, the first
three lanes are: DNA molecular weight marker (I); PCR blank control (2);
and RT-PCR blank control (3); respectively. For the remaining lanes, each
lane represents a result from an individual animal. There are eight animals
in each group. Panel B: Densitometric results after the PAGE gels were
scanned in a Betagen analyzer.
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correlation factor of 0.98. This commercially available purified bovine ChAT protein
was therefore used as a positive control for Western blot analysis in all of the
following experiments.
Next, the total protein isolated from rat brain tissue was subjected to the same
analysis. Unexpectedly, two bands were observed from the rat brain tissue protein
samples, at MW = 67 kD, and MW = 45 kD, respectively. Both bands were
recognized by the same monoclonal antibody. When the linearization experiment was
conducted, the densities of both protein bands also showed dose-dependent changes
(Figure 15).
The protein amount was read from the protein band and calculated for each
individual sample as:
0.D. of protein= area of band x (O.D. of band - O.D. of background).
O.D. =mean of optical density.

The calculation of the expression of protein is similar to step 2-4 of the
calculation of expression of ChAT mRNA (page 59 &-67). However, reading of O.D.
was using for protein instead of using the R for mRNA.
E. 2. Septo-Hippocampal Pathway:
In the septum (Figure 16), a single icv injection of AF64A induced a transient
increase in the expression of the 67 kD protein (F(I,5) = 7.46, P < 0.05). Statistical
analysis indicated that there was no significant AF64A treatment x time course
interaction (F( 4,20) = 1.56, P = 0.22). A significant increase in the amount of 67 kD
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protein was first observed at day 2 (143.4 % of control, P <0.05), which peaked at day
4 (+150%, P<0.05) and was reduced to control levels at day 28. Meanwhile, there was
a more extensive and long-lasting increase in the expression of the 45 kD protein.
Statistical analysis indicated that there was a significant AF64A treatment x time
course interaction occurred (F(4,20)

=

19.45, P < 0.0001). There was a significant

alteration in the amount of the 45 kD ChAT protein following the AF64A treatment
(F(I,5)

=

302.66, P < 0.0001) and over the time course (F{4,20)

=

23.95, P < 0.0001)

in the septum. The increase in the 45 kD protein was observed at the first time point
(day 1, 639.9 % of control, P < 0.01) and peaked at day 2 (+1407%, P < 0.01); the
level of the 45 kD protein remained at a high level for at least for 28 days ( 190. 7 % of
control, P < 0.5) after the infusion of AF64A. When the septal proteins from day two
were tested, two commercially available ChAT proteins, human placenta and bovine
brain, respectively, were used as positive controls. In addition to the high molecular
weight protein band, a faint band at molecular weight of 45 kD was also observed in
both of these purified ChAT proteins.
In the hippocampus (Figure 17), unlike the results from the ChAT activity
assay, there was no immediate decrease in the amount of the 67 kD ChAT protein.
Statistical analysis indicated that there was a significant AF64A treatment x time
course interaction (F{4,32) = 7.86, P =0.002). There was a significant alteration in the
amount of the 67 kD protein following AF64A treatment (F{l,8) = 24.41, P = 0.001)
and over the time course observed (F{4,32) = 7.11, P = 0.0003). The decrease of this
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protein was first observed at day 4 (down to 53.5 % of control, P < 0.01) following
treatment with AF64A. This change appears to be long-lasting; the 67 kD expression
in the hippocampus was still low at the last time point measured, on day 28 (56.5 % of
control, P < 0.01). There also was an alteration in the amount of the 45 kD protein in
the hippocampus. Statistical analysis indicated that there was a significant AF64A
treatment x time course interaction (F(4,32)

=

2.91, P

=

0.037). There was a

significant alteration in the amount of the 45 kD protein following the AF64A
treatment (F(l,8)
4.42, P

=

= 24.66, P = 0.001) and over the time course observed (F(4,32)

=

0.006). This increase in the 45 kD protein lasted from day 2 to day 7

following AF64A administration (180 % of control, P < 0.05).
E.3. Striatum
In the striatum (Figure 18), a single icv injection of AF64A did not significantly
affect the expression of the 67 kD protein which corresponded to the results of ChAT
activity analysis. Statistical analysis indicated that there was no significant AF64A
treatment x time course interaction (F(4,24)

=

0.67, P = 0.62). There was no

significant alteration in the amount of the 67 kD protein following AF64A treatment
(F{l,6)

=

3, P

=

0.13) and over the time course observed (F(4,24)

=

0.92, P

=

0.47.

However, there was a significant change in the amount of the 45 KD protein.
Statistical analysis indicated that there was a significant AF64A treatment x time
course interaction (F(4,24)

=

6.69, P

=

0.0009). There was a significant alteration in

the amount of the 45 kD protein following AF64A treatment (F(l,6) = 75.75, P =
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Figure 14: Correlation of Western blot analysis for the measurement of ChAT protein
amounts. Panel A: Autoradiograph of Western blot analysis. Different
amounts of purified bovine ChAT protein, commercially available, were
loaded on the 7.5 % SDS-PAGE gel. The expected molecular weights of
this protein were 68 & 66 kD. Panel B: Densitometric results after the
autoradiograph was scanned in an NIH Image 1.57 System. The density
from both bands was counted.
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Figure 15: Linearization of tissue ChAT protein. Panel A: Autoradiograph of the
Western blot analysis. Different amounts of total protein from septum
were loaded on the 7.5 % SDS-PAGE gel. Two proteins with different
molecular weight (67 & 45 kD, respectively) were detected. Al. Septal
tissue harvested from AF64A treated animals. A2. Septal tissue harvested
from control animals. Panel B: Densitometric results after the
autoradiograph was scanned in an NIH Image 1.57 System. The density
from both bands was counted.
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Figure 16: Effect of AF64A on ChAT protein expression in the septum. Animals were
decapitated at different time points after icv administration of AF64A (1
nmol/side, bilaterally). Western blot analysis was performed by using total
protein isolated from septal tissue according to the procedure described in
the Methods chapter. The data were obtained from 5-6 animals per group.
Statistical significance was calculated from a comparison of the AF64A
and vehicle-injected rats, at the same time point (Newman-Keuls' test). * P
< 0.05; ** P < 0.01. Panel A: Autoradiographs of Western blot analysis.
Each autoradiograph represents the result from one time point. In panels
Al, A3, A4 and AS, starting from the left, the first lane was loaded with
purified bovine ChAT protein as positive control. For the remaining lanes,
each lane represents a result from an individual animal. There were 5-6
animals in each group. Panel B: Densitometric results after the films were
scanned in an NIH Image 1.57 System. B 1 shows the data for the 67 kD
protein. B2 shows the data for the 45 kD protein (common log scale for
the Y-axis).
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Figure 17: Effect of AF64A on ChAT protein expression in the hippocampus.
Animals were decapitated at different time points after icv administration
of AF64A (I nmol/side, bilaterally). Western blot analysis was performed
by using total protein isolated from hippocampal tissue according to the
procedure described in the Methods chapter. The data were obtained from
7 animals per group. Statistical significance was calculated from a
comparison of the AF64A and vehicle-injected rats, at the same time point
(Newman-Keuls' test) * P < 0.05~ ** P < 0.01. Panel A: Autoradiographs
of Western blot analysis. Each autoradiograph represents the result from
one time point. Starting from the left, the first lane is purified bovine
ChAT protein. For the remaining lanes, each lane represents a result from
an individual animal. There are 7 animals in each group. Panel B:
Densitometric results after the films were scanned in an NIH Image 1.57
System. BI shows the data for the 67 kD protein. B2 shows the data for
the 45 kD protein (common log scale for the Y-axis).
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Figure 18: Effect of AF64A on ChAT protein expression in the striatum. Animals
were decapitated at different time points after icv administration of
AF64A (1 nmol/side, bilaterally). Western blot analysis was performed by
using total protein isolated from striatal tissue according to the procedure
described in the Methods chapter. The data were obtained from 4 - 7
animals per group. Statistical significance was calculated from a
comparison of the AF64A and vehicle-injected rats, at the same time point
(Newman-Keuls' test) * P < 0.05~ ** P < 0.01. Panel A: Autoradiographs
of Western blot of analysis. Each autoradiograph represents the result
from one time point. Starting from the left, the first lane is purified bovine
ChAT protein. For the remaining lanes, each lane represents a result from
an individual animal. There are 4 - 7 animals in each group. Panel B:
Densitometric results after the films were scanned in an NIH Image 1.57
System. B 1 shows the data for the 67 kD protein. B2 shows the data for
the 45 kD protein (common log scale for the Y-axis).
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0.0001) and over the time course observed (F(4,24)

=

8.95, P = 0.0001) in the

striatum. The increase of the amount of the 45 kD protein peaked at day 2 (558.4 % of
control, P < 0.01) after the treatment with AF64A; this increase was observed at all the
time points, with statistical significance (Figure 18).
Generally, changes in the expression of 67 kD protein were paralleled by
changes in ChAT activity in all brain regions which have been observed. However,
there was no relationship between changes in the amount of 45 kD protein and ChAT
activity.

F. In Vitro Studies ofChAT Protein:
Since the amount of the low molecular weight protein (MW. 45 kD) increased
significantly after AF64A treatment in all brain regions which were studied, there was
a possibility that AF64A might bind to ChAT protein and break it down to smaller
molecules. The following in vitro experiments were conducted to test this hypothesis.
F. 1. Effect of AF64A on Purified Bovine ChAT Protein.
Co-incubation of AF64A (0.5 µM - 0.5 mM) with purified bovine ChAT
protein (37°C, 30 minutes) caused a significant decrease in ChAT activity in a dose
dependent manner (Ki

=

0.1 mM), without significant change in ChAT protein

amounts at MW 68 & 66 kD. There were also no other new bands appearing following
AF64A treatment (Figure 19).
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F. 2. Effect of AF64A on ChAT Protein in Tissue Homogenates.
Co-incubation of AF64A (S µM - 5 mM) with tissue homogenate (from rat
striatum) caused a significant decrease in ChAT activity in a dose dependent manner
(Ki = I mM) without significant changes in ChAT protein amounts at either molecular
weight of 67 kD or 45 kD (Figure 20).
These data suggest that AF64A reduces ChAT activity by masking the active
site of the enzyme rather than by breaking this protein down to smaller molecules.
F. 3. The 45 kD Protein is an Unstable Protein.
During the above experiments, protein was stored in a 1% SDS solution and in
the presence of the proteinase inhibitor PSMF. However, following repeated freezing,
thawing, and heating up to 95°C several times, the 45 kD protein disappeared from the
Western blot. Meanwhile, no significant changes in the 67 kD protein were observed.
This result suggests that the 45 kD protein is less stable than the 67 kD protein (Figure
21).
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Figure 19: Effect of AF64A on purified ChAT protein. Different concentrations of
AF64A (0.5 µM - 0.5 mM) were incubated with purified ChAT protein for
30 minutes at 37°C. Then the protein samples were subjected to the ChAT
activity assay and Western blot analysis.

99

0

-e
.......
c

I

125

125

100

100

0

()

'....__
Cf2.
>.
.......

">

ts

<(

I-

75

::::J'"

)>
_.._-f

'Cf2. ...,
"U

()0

o

50
25

<(

50

0

ro

:::::J :::::J·

...+

a)>

•

..::::; 3

ChAT Activity
ChAT Protein MW= 67 kD
ChAT Protein MW= 45 kD

A

0

...c

()

75

()

10-5

104

10-3

25

:::::J

...+

10-2

0

Concentration of AF64A (M)

Increase in the concentration of AF64A
MW
68,000
66,000
45,000

68,000
66,000
45,000

Purified Bovine
ChAT Protein

0

c

100

Figure 20: Effect of AF64A on ChAT protein of tissue homogenate. Different
concentrations of AF64A (5 µM - 5 mM) were incubated with tissue
homogenate (striatal tissue from untreated rats) for 30 minutes at 37°C.
Then the protein samples were subjected to the ChAT activity assay and
W estem blot analysis.
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Figure 21. Autoradiographs for Western blot analysis. The protein samples used for

both experiments are identical~, they are the proteins which were isolated
from day 2 striatum. A. Protein loading samples were prepared freshly
before loading for electrophoresis. Both molecular bands were detected. B.
Protein samples which had been frozen, thawed and heated to 95°C for 5
min. a couple of times before loading. The low molecular weight bands
have disappeared in this autoradiograph.

CHAPTERV
DISCUSSION
The actions of AF64A have been widely studied, and several possible targets of
AF64A action have been reported, which include the HAChT (Curti and Marchbanks,
1982; Uney and Marchbanks, 1987), ChAT protein (Sandberg et al., 1985), and axonal
transport (Kasa and Hanin, 1985) of the cholinergic neuron (Figure 22).
Since AF64A is structurally a mustard, it is possible that AF64A directly alkylates
the molecules of the HAChT and ChAT proteins, as well as those proteins that are
involved in the axonal transport mechanisms of cholinergic neurons (Calabresi and
Chabner, 1990). The alkylation of these molecules would affect their function, which could
appear as a decrease in the activity of ChAT and HAChT, and blockade of axonal
transport, respectively. According to previous studies, a single icv dose of AF64A
administration causes long term (months) damage in the central cholinergic system of
animals (Fisher et al., 1986; Leventer et al., 1987; Hortnagl et al., 1991; El Tamer et al.,
1992). If this long-lasting deficit of cholinergic function was caused by a direct effect of
AF64A on any or all of those molecules, then AF64A would have to be in its active form
for a very long time period, since all of these molecules have a relatively rapid turnover
time. For example, the half life of ChAT protein is only several days (Hersh, 1992;
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and Mahler, 1975). Any ChAT protein damaged directly by AF64A would not stay in the
tissue too long, since it would be rapidly replaced by newly synthesized molecules.
Therefore, to induce a long term cholinergic deficiency by directly acting on these
molecules, the active form of AF64A would have to be present in tissues for the duration
of the study; and constantly alkylate those newly synthesized molecules to induce their
functional deficit. However, AF64A has a very short half life (Pilar et al., 1987; Goldstein
et al., 1988) at physiological conditions, which is about 3-6 hours in CSP (pH= 7.4, and
37°C). A chemical with such a short half life (hours) appears to have a long lasting
(months) toxicity in vivo, which is difficult to explain by AF64A only acting on the ChAT
protein or HAChT themselves. There are several possibilities which could cause a longterm decrease in these parameters in the hippocampus. These include: 1) A loss of
cholinergic innervation in the hippocampus; and/or 2) AF64A damage of DNA molecules
of cholinergic neurons in the septo-hippocampal pathway. The damage of DNA
molecules in cholinergic neurons could subsequently cause a decrease in the transcription
of mRNA and translation of protein, which would finally appear as a functional reduction
in the cholinergic neurons. This dissertation has focused on the second possibility.
The possibility of AF64A targeting DNA molecules was considered since AF64A
is structurally similar to other nitrogen mustard (HN2) compounds (Figure 3). HN2 is a
member of a family of alkylating agents which are used for the chemotherapy of
neoplastic diseases (Lawley and Brookes, 1965; Calabresi and Chabner, 1990). The
chemotherapeutic and cytotoxic effects of HN2 are directly related to the alkylation of
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DNA. The 7 nitrogen atom of guanine is particularly susceptible to the formation of a
covalent bond with both monofunctional and bifunctional alkylation of nitrogen mustards.
However, this does not exclude the possibility that other sites in the DNA may also be
attacked; thus, other atoms in the purine and pyrimidine bases of DNA may also be
alkylated to a lesser degree by HN2, such as the phosphate atoms of the DNA chains and
the proteins associated with DNA (Lawley and Brookes, 1965; Calabresi and Chabner,
1990).
Up to now, in vitro and cell culture experiments, which had been conducted to test
the effects of AF64A at the gene level, are consistent with this hypothesis. In vitro
(Futscher et al., 1992; Lev-Lehman et al., 1994; Hanin et al., 1995) and cell culture studies
(Futscher et al., 1992; Santiago et al., 1992; Santiago, 1995) strongly support the
hypothesis of AF64A acting on DNA molecules. However, whether AF64A acts in vivo
by a similar mechanism has not yet been demonstrated. In a study employing cell culture,
the neuroblastoma (LA-N-2) cell line was used by Santiago (1995); AF64A can be readily
taken up directly into the cell body where the nucleus is located. In the in vitro studies
AF64A was directly incubated with naked DNA molecules. Thus, in both preparations
studied so far, AF64A has had an excellent chance to react with DNA molecules, and thus
to cause DNA damage.
However, there are differences between in vitro, and in vivo studies. As shown in
Figure 22, in the septo-hippocampal cholinergic pathway cholinergic neuron cell bodies
are located in the septum, and project long axons into the hippocampus (Butcher and
Woolf, 1986). A HAChT system primarily exists at the nerve terminal (Guyenet et al.,
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1973; Suszkiw and Pilar, 1976; Kuhar and Murrin, 1978; Jope, 1979); which means that,
in the case of the septo-hippocampal pathway, the HAChT system exists mainly in the
hippocampus. It is known that uptake of AF64A into cholinergic neuron occurs via the
HAChT system when low doses of AF64A are used. Thus, in vivo, if the effect of AF64A
is exerted at the cell body, after delivery into the lateral ventricles, AF64A would have to
be taken up by the HAChT in the hippocampus and transported in a retrograde manner
into the cell body of these cholinergic neurons, which are in the septum.
Only after AF64A has arrived in the cell body where the nucleus is located, would
it be possible for it to act directly on the DNA molecules of the cholinergic neurons. In this
case, a decrease in the steady state level of ChAT mRNA would be expected to appear, as
has been observed in the cell culture studies (Santiago, 1995), since the damage of DNA
molecules by AF64A would affect the gene transcription rate, resulting subsequently in a
decrease in ChAT mRNA levels.
Based on all of the above information, this project was developed to test the
HYPOTHESIS that: in vivo, AF64A induces a long-lasting cholinergic hypofunction
by damaging the DNA molecules of cholinergic neurons, which subsequently induces
a decrease in gene transcription and translation.

A Response of the Septo-Hippocampal Cholinergic Pathway to icv AF64A Infusion
The response of the septo-hippocampal cholinergic pathway to the icv AF64A
infusion was variable, in different parts of the pathway, and at different time points.
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One day after the treatment, there was an immediate decrease in ChAT activity in
the hippocampus (Figure 4) without any change in ChAT protein amount in the same
brain region (Figure 17, Al). Concomitantly, a significant increase in ChAT mRNA levels
was observed in the septum (Figure 12, Al), which was followed by an increase in the 67
kD ChAT protein content (Figure 16, A2), as well as in ChAT activity (Figure 5) in the
septum, by the next day. ChAT mRNA levels reduced below control level 7 days after the
administration of AF64A and stayed at this low level for at least four weeks in the septum
(Figure 12, B). Meanwhile, ChAT activity continually remained low in the hippocampus,
and this was matched with the decrease in the amount of the 67 kD ChAT protein starting
from 4 days after the treatment (Figure 17, A3-A5).
The long term effects of AF64A, which include the long lasting decrease in ChAT
mRNA level in the septum and decrease in ChAT protein and ChAT activity in the
hippocampus, agree with my hypothesis as stated above. However, the increase in ChAT
mRNA in the septum at this early stage was not expected.

A 1. Elevation of ChAT mRNA and Protein in the Septum at an Early Stage.
The steady state level of mRNA is balanced by its synthesis and degradation.
Therefore, this elevation in steady state expression of ChAT mRNA in the early stage of
the experiment could be due to: 1) an increase in the transcription of the ChAT gene; 2) a
decrease in the degradation ofChAT mRNA; or 3) both.
The best way to test the first possibility was to determine the transcription rate of
ChAT gene by using a nuclear run-on analysis. However, due to relatively low
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transcription levels of ChAT gene in brain tissue (Cavicchioli, 1991 ), there have been no
reports on the measurement of the transcription rate of this particular gene. So, the first
possibility could not be tested directly, although, it is very possible that the increase in
ChAT mRNA levels in the septum may be due to a up-regulation of transcription of the
ChATgene.
The studies conducted on primary culture of rat sympathetic neurons indicate
that neuronal activity determines the level of mRNA by regulating the transcription
rate of the ChAT gene (Brice et al., 1989). When these sympathetic neurons were
cultured in a muscle-conditioned medium, the expression of ChAT mRNA was upregulated.
More information about the regulation of ChAT mRNA expression has been
obtained from studies on a simple in vivo system, Drosophila, using wild type and
temperature-sensitive mutant flies. It appears that both a positive and negative
feedback mechanism contribute to the regulation of the expression of ChAT mRNA
in Drosophila (Tijima and Salvaterra, 1992). When Drosophila were placed at higher
temperature (restrictive temperature 30°C), a higher level of ChAT mRNA was
detected in wild type flies compared to flies which were placed under permissive
temperature (18°C). This reflects a higher demand for ACh to sustain cholinergic
synaptic transmission at the higher temperature.
All these studies have provided clues that a demand for neuronal activity could
be a regulator of ChAT gene expression. When higher neuronal activity is required,
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target cells may conceivably generate more trophic factors, or some unidentified
signal system in the cholinergic neuron may be triggered, resulting in an up-regulation
of the function of the whole system.
The exact mechanism for the regulation of the expression of ChAT mRNA in
rat brain has not yet been clarified. However, there are some factors which could
enhance cholinergic function by up-regulating gene expression of cholinergic
neurons, such as NGF (Cavicchioli et al., 1991 ), which is derived from the target cells
of cholinergic neurons. This trophic polypeptide is necessary for the normal
development and survival of certain populations of neurons in the central nervous
system (CNS) and peripheral nervous system (PNS), especially cholinergic neurons.
It has been reported that injury in the axon of cholinergic neurons could cause an
increase in ChAT mRNA levels. This phenomenon has been observed both in the PNS
and the CNS (Ibanez et al., 1991; Weiser et al., 1994). In the peripheral system, an
increase in ChAT mRNA expression following axonal injury has been explained as being
due to an up-regulation of the ChAT gene. It is believed that an increase of ChAT mRNA
expression is necessary for regeneration of motor neurons (Ibanez et al., 1991). There is a
hypothesis to explain the above phenomenon which occurs in PNS: 1) Axonal injury or
denervation of motor neurons (initial insult) will reduce ACh release; 2) Decrease in
cholinergic function will trigger muscle cells to synthesize and release more NGF; and 3)
NGF will promote motor neuron sprouting and up-regulation of ChAT expression
(compensatory response). However, in the CNS, a similar compensatory effect is
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incomplete. Damage caused by the initial insult might exceed the compensatory effect,
and thus result in loss of neurons. In this case, exogenous NGF delivery might help
support survival of cholinergic neurons (Stewart and Appel, 1988).
In the present in vivo studies, icv AF64A infusion caused an initial functional
cholinergic decrease in nerve terminals, which appeared as a decrease in ACh, and in
the activity of ChAT and HAChT in the hippocampus. This disequilibrium, in the
form of a lower cholinergic neuronal activity with the relative high target demand,
might trigger a compensatory mechanism as described above.
However, this is still an assumption. If a more sensitive method, which could be
used to test gene transcription rate, was available, a positive experimental result which
confirmed the up-regulation of the transcription of the ChAT gene, would be convincing.
The second possibility which could conceivably cause an increase in ChAT
mRNA levels in the septum is one in which AF64A treatment affects the stability of
ChAT mRNA. AF64A might cause a decrease in the degradation of ChAT mRNA, which
would cause an elevation of ChAT mRNA levels in the cholinergic neuron. To eliminate
this possibility, the stability ofChAT mRNA has to be tested following AF64A treatment.
Actinomycin D, an RNA transcription inhibitor, could be used in this experiment.
Administration of actinomycin would exclude the effect of gene transcription. Following
the infusion of actinomycin D with AF64A or vehicle, comparing ChAT mRNA levels in
the septum between these two groups could give a clue whether AF64A treatment alters
the stability ofChAT mRNA.
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Thus, the following sequence of events was proposed to explain the
mechanism of action of AF64A on ChAT mRNA expression in the septohippocampal cholinergic neuron in vivo in the early stage: I) An rapid decrease in
ChAT activity (Figure 4) in the hippocampus following AF64A infusion is observed.
A concurrent decrease in the cholinergic neurotransmitter, ACh, the product of ChAT,
had also been reported earlier (Leventer et al., 1986). 2) The reduction of neuronal
activity in the nerve terminal triggers certain signal systems which activate the
function of the cell body of the cholinergic neuron by a feedback regulation. 3) The
cell body, trying to compensate for the functional reduction occurring at the nerve
terminal over-expresses some genes, such as the functional enzyme ChAT; this first
appears as an increase in the steady state level of ChAT mRNA, followed by an
increase in the amount of ChAT protein and ChAT activity in the septum.
A. 2. Long-Lasting Reduction ofChAT mRNA in the Septum.
The decrease in ChAT mRNA level in the septum, which happens at a later
stage following administration of AF64A (7 days to 4 weeks), occurs in parallel with
a long term decrease in protein amount and activity of ChAT in the hippocampus.
This alteration is in response to the long term deficit of cholinergic function in the
septo-hippocampal pathway. The long-lasting decrease in ChAT mRNA in the septum
might be due to a decrease in gene transcription which results from the direct effect of
AF64A at the gene level, similar to what has been inferred in the cell culture and in

vitro studies.
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Mustard agents cause DNA damage without gene selectivity. Besides the
ChAT gene, AF64A could also damage other genes. The effect of AF64A on other
genes which are necessary to keep the neurons alive, such as the house keeping genes,
might affect the viability of these affected cholinergic neurons. The final result could
be the cell death which appears as a loss of cholinergic neurons in the septum.
Immunocytochemical studies have been conducted to explore whether there is
a loss of cholinergic neurons following AF64A treatment. There were significant
decreases in the number of ChAT immunoreactive (ChAT-IR) neurons in the septum,
1-3 months after icv AF64A infusion (Chrobak et al., 1988; Lorens et al., 1991 ).
Double-labeling experiments, using the retrograde fluorescent tracer, FluoroGold,
combined with immunocytochemistry for ChAT, confirmed that there was death of
cholinergic neurons in the septum following icv AF64A infusion (Lorens, S. A.,
personal communication). Administering AF64A directly into the hippocampus
(Messer et al., 1991; Tonnaer et al., 1986) or cortex (Mouton and Arendash, 1990)
also induced similar morphological changes in cholinergic cell bodies in the septum.
However, despite the direct effect of AF64A on DNA molecules causing the
cell death that has been described above, there is another possibility that might explain
the observed loss of cholinergic neurons in the septum. AF64A may have an effect
only at cholinergic nerve terminals, which would initiate a retrograde degeneration of
the cholinergic neurons.

114

As early as 1986, it has been reported that 1cv infusion of AF64A (5
nmol/lateral ventricle) caused a specific degeneration of cholinergic axons in the
septo-hippocampal pathway, without influencing neuronal perikarya and noncholinergic fibers (Kasa et al., 1986). A similar phenomenon was reported in other
cholinergic pathways (Morley et al. 1991; and Stephens et al., 1986). Furthermore,
primary cell culture studies showed that there was a cholinergic cell loss following
incubation with AF64A, and the surviving cholinergic neurons appeared with intact
somata but damaged processes (Amir et al., 1988). All these data indicate that a
retrograde degeneration is induced by AF64A, and that it starts at the nerve terminal.
This retrograde degeneration might occur because of an impairment of trophic factor
function, or due to an inadequacy of trophic effects to keep pace with the damage of
cholinergic nerve terminals and axons by AF64A (Stewart and Appel, 1988). The
massive loss of cholinergic neurons in the septum caused by retrograde degeneration
might also result in a decrease in ChAT mRNA levels in this brain region.
There are, therefore, two possibilities that now may be responsible for the
decrease in the ChAT mRNA expression and loss of cholinergic neurons in the
septum. They are: 1) AF64A causes extensive gene damage in cholinergic neurons
when it arrives at the cell bodies in the septum by retrograde transport from
hippocampus, which finally affects the viability of the cell and causes cell death; or 2)
AF64A acts only at cholinergic nerve terminals and/or axons, which initiates a
retrograde degeneration of the cholinergic neuron mimicking the effect of axotomy.

115

Both of these effects would result in a loss of ChAT-IR neurons and a decrease in
expression ofChAT mRNA in the septum.
Axotomy caused retrograde degeneration m septo-hippocampal cholinergic
neurons has been reported (Hefti, 1986). The injury occurring at these axons induced
a transient increase, followed by a long lasting decrease in ChAT mRNA expression
in the septum, which is similar to what was observed in this AF64A study. According
to the in situ hybridization study, axotomy induced up-regulation of ChAT mRNA,
which peaked at 7 days after the surgery, and returned to control levels in about two
weeks (Weiser et al., 1994). Unlike the response to the axotomy, a rapid drop in
ChAT mRNA within one week was observed in the septum (Figure 12) in AF64A
studies. The time period of changes in ChAT mRNA levels does not coincide in these
two different studies.
Furthermore, electron microscopic examination combined with Fluoro-Gold
retrograde tracing showed that axotomy of the septo-hippocampal projection neurons
significantly attenuates the expression of transmitter-synthesizing enzymes and causes
cell shrinkage. Nevertheless, a majority (>70%) of the cells survived for extended
periods of time (10 weeks) (Naumann et al., 1992). However, a significant loss of
ChAT-IR neurons (36-51%) has been observed as early as 4 weeks following icv
AF64A infusion (Lorens et al., 1991).
Therefore, the long lasting decrease in cholinergic function and loss of ChATIR neurons might be due to the combination of both possibilities (direct effect of
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AF64A on gene level and retrograde degeneration), but, the rapid drop in ChAT
mRNA is more likely due to a direct effect of AF64A on DNA molecules of
cholinergic neurons. Possibly, a double tracer immunocytochemistry, and an in situ
hybridization parallel study concerning ChAT in the septum at earlier time-points,
would help to clarify the problem, since we have observed a decrease in ChAT
mRNA in the septum as early as 7 days after AF64A administration.
A. 3. Alterations of ChAT Protein in the Septo-Hippocampal Pathway.
As a protein, ChAT, the key enzyme in acetylcholine (ACh) synthesis, has been
studied for years. It has been suggested that this enzyme is a single peptide protein,
encoded by a single gene with a predicted molecular weight of about 72 kD in rat brain
tissue (Brice et al., 1989), although the purified ChAT protein measures at about 67 kD in
SDS-PAGE gel analysis (Dietz, 1980). In the current study, the monoclonal anti-ChAT
antibody recognized two proteins with molecular weight of about 67 kD and 45 kD,
respectively (Figure 15).
In the septum, the alteration of the expression of the 67 kD protein was closely

related to the change in ChAT activity (Figure 5, and Figure 16, B 1). However, there was
no close relationship between the expression of the 45 kD protein and ChAT activity
(Figure 5, and Figure 16,

B2)~

the extensive increase in the expression of the 45 kD

protein following AF64A administration was not accompanied by an increase in ChAT
activity.
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The anti-ChAT antibody used in this study recognizes ChAT protein in an epitope
different from the active sites of this enzyme. Thus, even if the active sites of ChAT
protein were masked by AF64A and lost their function (Sandberg, 1985), the ChAT
protein could still be tested by this antibody. In the hippocampus, the decrease in 67 kD
protein expression appeared several days later than the decrease in ChAT activity,
implying that, in the very early stage, the decrease in ChAT activity in the hippocampus
might be due to a direct alkylating effect of AF64A on ChAT protein. So, in the first two
days, although normal amounts of ChAT protein existed in this brain region (Figure 17),
the decrease in cholinergic function was still observed (Figure 4). To eliminate the gap
between ChAT protein content and enzyme activity, the system needs several days to
replace these alkylated ChAT proteins since the normal half life of ChAT protein is 5.6
days (Wenthold and Mahler, 1975). Therefore, the parallel decrease in both ChAT protein
and ChAT activity later on in the hippocampus indicated that the long lasting decrease in
ChAT activity in the hippocampus was due to a decrease in the amount of ChAT protein
(Figure 4; and Figure 17, B 1).
A. 4. Overall summary of the Response of the Septo-Hippocampal Cholinergic

Pathway to AF64A icv Infusion.
As shown in Figure 23, after icv administration, AF64A diffuses into the

hippocampus which is adjacent to the lateral ventricle, where it is taken up by
HAChT(which primarily exists in cholinergic nerve terminals) into cholinergic neurons
and is accumulated inside the neuron. AF64A first causes local damage at the nerve
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terminal, which includes direct binding with ChAT proteins, resulting in a reduction in
neuronal activity in the hippocampus. This acute insult to cholinergic nerve terminals
triggers a compensatory reaction by the cholinergic neuron, which results in a transient
increase in the expression of ChAT mRNA and ChAT protein in the septum. At a later
stage, due to an inhibitory effect by AF64A on gene expression of cholinergic neurons, the
expression in both parameters (ChAT mRNA and ChAT protein) is reduced. Meanwhile,
axonal transport is also affected by AF64A (Kasa and Hanin, 1985). This induces some
accumulation of synthesized ChAT in the cholinergic cell body, which helps to maintain
ChAT protein amount and activity at normal levels in the septum. However, in the interim,
there is a severe shortage of ChAT protein in the hippocampus, which appears as a long
lasting significant decrease in ChAT activity at this site. The alteration in the amounts of
the 67 kD ChAT protein in the hippocampus was significant correlated with the change in
ChAT mRNA levels in the septum ( r= 0.37, P < 0.01).
Changes in levels of the 45 kD protein after AF64A administration did not
agree with changes in ChAT activity both in the septum and in the hippocampus.
More about this protein will be discussed later.

B. Response of the Striatal Cholinergic Region to icv AF64A Infusion

The striatum is another brain region abundant cholinergic neurons, which also
is anatomically adjacent to the lateral ventricle. Cholinergic neurons in the striatum
are interneurons; their cell bodies, axons and nerve terminals are all contained within
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the striatum (Butcher and Woolf, 1986). This anatomical characteristic of cholinergic
neurons in the striatum is different from that of cells in the septo-hippocampal
pathway. Therefore, the effect of AF64A on the striatum was also tested in these
studies.
There was no significant change in ChAT activity in the striatum following
AF64A treatment (Figure 6), which raises several possibilities: 1) The cholinergic
neurons in the striatum might be resistant to AF64A action; 2) Similar changes to
those seen in the septo-hippocampal pathway might occur in the striatum, however,
the time scale for these effects is different from that in the septo-hippocampal
pathway. Striatal cholinergic interneurons might recover faster from AF64A damage
compared to the septo-hippocampal cholinergic pathway. 3) In view of the previous
findings showing that ChAT activity is altered in different directions at the cell body
and the nerve terminal in the septo-hippocampal cholinergic pathway following
AF64A treatment (Figure 4, and Figure 5), the possibility cannot be excluded that
similar changes also happened in the striatum. If opposite changes in the cell body
and nerve terminal also happened in the striatum, the changes of ChAT activity in cell
body and nerve terminal might compensate for each other. Thus, a significant change
in ChAT activity would not be observed. In this case, ChAT activity from the striatal
tissue homogenates is not the best marker to measure the effect of AF64A on striatal
cholinergic system.
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With this in mind, the expression of ChAT mRNA in the striatum was
measured, with the hope of observing a change in expression of ChAT mRNA in the
striatum, similar to what was observed from the septo-hippocampal pathway.
However, in this study I did not observe any significant overall changes in ChAT
mRNA in the striatum, although there were large variations in measured levels of this
parameter within groups (Figure 13), therefore, the last possibility is eliminated.
In view of the considerations listed above, there are only two possibilities

available to explain the lack of any observed response in cholinergic neurons in the
striatum to AF64A treatment.
The first is that the cholinergic neuron in the striatum is relatively less sensitive
to AF64A compared to the septo-hippocampal pathway. The differential sensitivity of
different cholinergic pathways in the brain to AF64A has been reported before for
other cholinergic pathways (Morley et al., 1991; and Smith et al., 1989), and it might
relate to the density of the HAChT in the nerve terminals on different cholinergic
neurons (Gomez et al., 1993). However, the HAChT activity in the striatum is three
times higher than that in the hippocampus (our own, unpublished observations).
Furthermore, it has been shown that synapsomes prepared from both hippocampus
and striatum are equally sensitive to AF64A (Pittel et al., 1987). These studies
therefore do not support the hypothesis that the lesser sensitivity of striatum to AF64A
treatment results in a lesser change of ChAT mRNA and ChAT activity in that brain
region.
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It would appear, therefore, that the present studies may have missed the time
points in which one should observe change in ChAT mRNA and ChAT activity in the
striatum.
In primary neuron cell culture studies, AF64A induced a similar degree of

inhibition in ACh synthesis both in co-cultures of septum-hippocampus and cultures
of striatum. However, ACh-synthesis recovered more rapidly in the striatal cultures
then in septal-hippocampal co-cultures after AF64A washout (Meyer et al., 1993).
This indicates that there is a special processing mechanism in striatal cholinergic
neurons which helps them to recover rapidly from AF64A induced damage.
Further in vivo studies on ChAT protein amount in this brain region make this
assumption more plausible. Although no significant change was found in the 67 kD
protein (Figure 18, B 1), there was a tremendous increase in the amount of 45 kD
protein following AF64A treatment (Figure 18, B2). The extent and duration of time
of the increase of this low molecular weight protein was compatible to that which was
observed in the septum (Figure 16, B2).
This phenomenon indicates that the striatal cholinergic system does indeed
respond to AF64A treatment. However, its response is different from that of the
septo-hippocampal cholinergic pathway. Perhaps, a rapid recovery mechanism of
striatal cholinergic neurons plays an important role during the process.
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C. Response ofChAT Protein to AF64A Incubation
A monoclonal anti-ChAT antibody (Boehringer Mannheim, Clone 1.B3.9B.3)
was used in Western blotting analyses. Besides the expected 67 kD ChAT protein, a
45 kD protein also was recognized by this antibody. Linearization experiments showed
a good correlation between the density of the protein bands and the amount of protein
loaded (Figure 15), suggesting that this protein band was not an artificial phenomenon.
The low molecular weight protein also has been observed in purified ChAT proteins from
bovine brain and human placenta (Figure 16, A2 A4), although the signal is very faint.
These data suggest that this 45 kD protein is very closely related to ChAT protein, the 67
kD protein which has been reported before.
Following AF64A icv infusion, there was a significant increase in the expression
of the 45 kD protein in all the brain regions which were studied (Figure 16, 17, 18). The
most extensive and long lasting increase in this protein was found in the septum and
striatum, the brain regions where cholinergic neuron cell bodies exist.
This 45 kD protein could be one of the following: I) an isoform of ChAT protein;
2) a small molecule resulting from the breakdown of ChAT protein which was induced by
AF64A; 3) another protein sharing the same epitope with ChAT protein which is
recognized by the anti-ChAT antibody; or 4) ChAT protein which is translated from an
truncated ChAT mRNA induced by AF64A damage on the ChAT gene.
There have been no earlier reports on the low molecular weight ChAT protein in
rat brain. Therefore, I first considered this 45 kD protein as a degradation

produ~

of the

124

67 kD ChAT protein. To test whether AF64A could directly break down the 67 kD ChAT
protein to this low molecular weight protein, purified bovine ChAT protein (there is no
purified rat ChAT protein available) was incubated with different concentrations of
AF64A. Although AF64A caused a significant reduction in ChAT activity in a dosedependent manner, no significant changes were observed in the protein amount, nor in the
molecular weights (Figure 19). At this point, I considered that the breakdown of ChAT
protein by AF64A might need some additional factors which exist in tissue. So, in the next
experiment, tissue homogenates were incubated with varied concentrations of AF64A. As
was observed in the purified enzyme study, there were no significant changes in either
molecular weight protein, although AF64A did cause a decrease in ChAT activity in the
tissue homogenates in a dose-dependent manner (Figure 20).
These in vitro studies suggested that AF64A reduces ChAT activity by masking
the active site of enzyme rather than by breaking this protein down to smaller
molecules, and that the 45 kD protein is not likely resulting from the breakdown of
the 67 kD protein.
Since this low molecular weight protein has also been observed in brain tissue
from control animals and purified ChAT protein (bovine and human), the data do not
support my last assumption, which means that the 45 kD protein most probably is not
translated from a truncated ChAT mRNA induced by AF64A treatment.
The protein is normally expressed in rat brain tissue, and the administration of
AF64A causes its over-expression. This protein could therefore be an isoform of the
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67 kD ChAT protein, or, another protein, which shares the same protein sequence
with the 67 kD protein.
In the early 1980s, possible multiple isoforms of ChAT protein had been
reported based on the solubilizing characterization of the enzymes; these were named
cytosolic ChAT and membrane bound ChAT, respectively (Benishin and Carroll,
1981; 1983 ). It was assumed that these two enzymes should be a little bit different in
their structure, since the latter one needs a lipophilic area to allow its binding with the
membrane. However, ChAT mRNA studies indicate that both of these enzymes have
an identical amino acid sequence (Habert et al., 1992).
A low molecular weight ChAT protein has been reported in bovine brain as 34
kD, however, no further information about this protein is available. No low molecular
weight ChAT protein has been reported in other mammalian species.
Due to the low expression of this 45 kD protein in normal rat brain, and its
unstable character (Figure 21 ), this protein is not easily noticed during the purification
of ChAT protein from normal animals. Protein sequencing or/and protein footprint
analysis could help to demonstrate whether this protein is an isoform of ChAT protein
and ~hether it shares its most amino acid sequence with that 67 kD protein. However,
purification of this protein would be a challenge due to the low expression and the
instability of this protein.
There is another possibility to explain this 45 kD protein. This protein might
not be related to the ChAT protein; however, it could possibly share certain amino
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acid sequence with the ChAT protein. This could cause an immuno-crossing
recognition by the anti-ChAT antibody which I used for the Western blot analysis.
When comparing ChAT protein to other cholinergic related proteins, it has
been reported that ChAT protein (Drosophila) shares a limited sequence homology
with AChE (Torpedo) and with the alpha subunit of nAChR (rat) (Mori et al., 1987;
Salveterra, 1987). This alpha subunit of nAChR expressed in rat brain tissue has 474
amino acids and a predicted molecular weight of 54.8 kD (Boulter et al., 1985),
although Western blot analysis on rat brain tissue showed that this alpha subunit
protein has a molecular weight of about 40 kD (Hawrot et al., 1986; and Reuss et al.,
1992). However, the Drosophila ChAT protein only shares a 60% sequence
homology with rat ChAT protein. The protein sequence homology between ChAT and
the alpha subunit of nAChR has not been reported. Western blot analysis using the
antibody against to this alpha-subunit of nAChR would help to solve this puzzle.

CHAPTER VI
SUMMARY
1. AF64A icv administration causes immediate inhibition of ChAT activity in the nerve

terminal (hippocampus) and triggers a compensatory response in the septohippocampal pathway.
2. Initially, AF64A causes an inhibition of hippocampal ChAT activity by directly
alkylating the active site of the ChAT protein.
3. The increase in septa! ChAT mRNA, 67 kD ChAT protein and ChAT activity is
transient.
4. The long-lasting decrease in ChAT activity in the hippocampus is due to a decrease in
the amount of the 67 kD ChAT protein in this brain region. These phenomena are
associated with the long-lasting decrease ChAT mRNA level in the septum.
5. AF64A did not cause significant changes in ChAT activity and ChAT mRNA
expression in the striatum over the time course observed.
6. AF64A caused a significant increase in the 45 kD putative ChAT protein in all tested
brain regions.
7. This study cannot exclude the possibility that disruption of cholinergic axonal
transport induced by AF64A also contributes to the long-lasting cholinergic
hypo function.
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